[S02DA03, antipyrine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Bupivacaine.]
[J01GA01, streptomycin, The risk or severity of methemoglobinemia can be increased when Streptomycin is combined with Bupivacaine.]
[L01AD04, streptozocin, The risk or severity of methemoglobinemia can be increased when Streptozocin is combined with Bupivacaine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bupivacaine.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[J01CG01, sulbactam, Levobupivacaine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01CA16, sulbenicillin, The risk or severity of methemoglobinemia can be increased when Sulbenicillin is combined with Bupivacaine.]
[S01AB04, sulfacetamide, The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Bupivacaine.]
[J01EC02, sulfadiazine, The risk or severity of methemoglobinemia can be increased when Sulfadiazine is combined with Bupivacaine.]
[J01ED07, sulfamerazine, The risk or severity of methemoglobinemia can be increased when Sulfamerazine is combined with Bupivacaine.]
[J01EC01, sulfamethoxazole, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Bupivacaine.]
[J01ED05, sulfamethoxypyridazine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxypyridazine is combined with Bupivacaine.]
[J01EB06, sulfanilamide, The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Bupivacaine.]
[J01EB04, sulfapyridine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Sulfapyridine.]
[S01AB02, sulfisoxazole, The risk or severity of methemoglobinemia can be increased when Sulfisoxazole is combined with Bupivacaine.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of methemoglobinemia can be increased when Sulthiame is combined with Bupivacaine.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01BB02, mercaptopurine, The risk or severity of methemoglobinemia can be increased when Mercaptopurine is combined with Bupivacaine.]
[N06DA01, tacrine, The metabolism of Levobupivacaine can be decreased when combined with Tacrine.]
[J01CA15, talampicillin, The risk or severity of methemoglobinemia can be increased when Talampicillin is combined with Bupivacaine.]
[L02BA01, tamoxifen, The risk or severity of methemoglobinemia can be increased when Tamoxifen is combined with Bupivacaine.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Levobupivacaine.]
[L01CB02, teniposide, The risk or severity of methemoglobinemia can be increased when Teniposide is combined with Bupivacaine.]
[R03CC03, terbutaline, Terbutaline may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[B01AE07, dabigatran etexilate, Levobupivacaine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Bupivacaine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Tetracaine.]
[S03AA02, tetracycline, The risk or severity of methemoglobinemia can be increased when Tetracycline is combined with Bupivacaine.]
[J01DI02, ceftaroline fosamil, The risk or severity of methemoglobinemia can be increased when Ceftaroline fosamil is combined with Bupivacaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Apomorphine.]
[L04AX02, thalidomide, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Bupivacaine.]
[P02CA02, thiabendazole, The metabolism of Levobupivacaine can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of methemoglobinemia can be increased when Eribulin is combined with Bupivacaine.]
[J01BA02, thiamphenicol, The risk or severity of methemoglobinemia can be increased when Thiamphenicol is combined with Bupivacaine.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiethylperazine.]
[L01AC01, thiotepa, The risk or severity of methemoglobinemia can be increased when Thiotepa is combined with Bupivacaine.]
[L01BB03, thioguanine, The risk or severity of methemoglobinemia can be increased when Tioguanine is combined with Bupivacaine.]
[N05CA19, thiopental, The risk or severity of methemoglobinemia can be increased when Thiopental is combined with Bupivacaine.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Bupivacaine can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Bupivacaine.]
[G04BE06, moxisylyte, Levobupivacaine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tiapride.]
[J01CA13, ticarcillin, The risk or severity of methemoglobinemia can be increased when Ticarcillin is combined with Bupivacaine.]
[B01AC05, ticlopidine, The metabolism of Bupivacaine can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tilidine.]
[S01ED01, timolol, The serum concentration of Bupivacaine can be increased when it is combined with Timolol.]
[P01AB02, tinidazole, The risk or severity of methemoglobinemia can be increased when Tinidazole is combined with Bupivacaine.]
[S01AA12, tobramycin, The risk or severity of methemoglobinemia can be increased when Tobramycin is combined with Bupivacaine.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tolazoline.]
[V04CA01, tolbutamide, Levobupivacaine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Levobupivacaine is combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Bupivacaine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Trazodone.]
[L01XF01, tretinoin, The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Bupivacaine.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Triamterene.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Triazolam.]
[C03AA06, trichlormethiazide, Bupivacaine may increase the hypotensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Levobupivacaine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Trifluoperazine.]
[S01AD02, trifluridine, The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Bupivacaine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Trifluperidol.]
[N05AA05, triflupromazine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of methemoglobinemia can be increased when Trimethadione is combined with Bupivacaine.]
[C02BA01, trimethaphan, Bupivacaine may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Bupivacaine.]
[R06AC04, tripelennamine, The metabolism of Bupivacaine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Triprolidine.]
[A03BB01, butylscopolamine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Bupivacaine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Bupivacaine can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Bupivacaine.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tubocurarine.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Levobupivacaine.]
[L01FX04, ipilimumab, The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Bupivacaine.]
[S01AA05, tyrothricin, The risk or severity of methemoglobinemia can be increased when Tyrothricin is combined with Bupivacaine.]
[L01EX04, vandetanib, The risk or severity of methemoglobinemia can be increased when Vandetanib is combined with Bupivacaine.]
[L01AD08, uracil mustard, The risk or severity of methemoglobinemia can be increased when Uracil mustard is combined with Bupivacaine.]
[R02AA14, oxyquinoline, Levobupivacaine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Bupivacaine can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Bupivacaine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Bupivacaine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Bupivacaine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Bupivacaine can be decreased when combined with Rilpivirine.]
[A07AA12, fidaxomicin, The risk or severity of methemoglobinemia can be increased when Fidaxomicin is combined with Bupivacaine.]
[S01AA28, vancomycin, The risk or severity of methemoglobinemia can be increased when Vancomycin is combined with Bupivacaine.]
[N03AX21, ezogabine, The risk or severity of methemoglobinemia can be increased when Ezogabine is combined with Bupivacaine.]
[B01AF01, rivaroxaban, Levobupivacaine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, The metabolism of Bupivacaine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Bupivacaine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The risk or severity of methemoglobinemia can be increased when Vinblastine is combined with Bupivacaine.]
[C04AX07, vincamine, The risk or severity of methemoglobinemia can be increased when Vincamine is combined with Bupivacaine.]
[L01CA02, vincristine, The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Bupivacaine.]
[L01CA03, vindesine, The risk or severity of methemoglobinemia can be increased when Vindesine is combined with Bupivacaine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[B01AA03, warfarin, Levobupivacaine may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[C03BA10, xipamide, Bupivacaine may increase the hypotensive activities of Xipamide.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Bupivacaine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of methemoglobinemia can be increased when Levetiracetam is combined with Bupivacaine.]
[L01EC01, vemurafenib, The risk or severity of methemoglobinemia can be increased when Vemurafenib is combined with Bupivacaine.]
[M05BA03, pamidronic acid, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Levobupivacaine.]
[L01FX05, brentuximab vedotin, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Bupivacaine.]
[M05BA05, tiludronic acid, Levobupivacaine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Levobupivacaine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The risk or severity of methemoglobinemia can be increased when Crizotinib is combined with Bupivacaine.]
[A02BC04, rabeprazole, Levobupivacaine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[L01XD05, temoporfin, The risk or severity of methemoglobinemia can be increased when Temoporfin is combined with Bupivacaine.]
[J01MA13, trovafloxacin, The risk or severity of methemoglobinemia can be increased when Trovafloxacin is combined with Bupivacaine.]
[L01XX02, asparaginase, The risk or severity of methemoglobinemia can be increased when Asparaginase Escherichia coli is combined with Bupivacaine.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Levobupivacaine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of methemoglobinemia can be increased when Alemtuzumab is combined with Bupivacaine.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ01, ruxolitinib, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Bupivacaine.]
[G04BD07, tolterodine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, The risk or severity of methemoglobinemia can be increased when Doripenem is combined with Bupivacaine.]
[C07AB03, atenolol, The serum concentration of Bupivacaine can be increased when it is combined with Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of methemoglobinemia can be increased when Peginterferon alfa-2a is combined with Levobupivacaine.]
[L01FA01, rituximab, The risk or severity of methemoglobinemia can be increased when Rituximab is combined with Bupivacaine.]
[J02AC03, voriconazole, The metabolism of Bupivacaine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Atracurium.]
[S01FA01, atropine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01XJ01, vismodegib, The risk or severity of methemoglobinemia can be increased when Vismodegib is combined with Bupivacaine.]
[L01EK01, axitinib, The risk or severity of methemoglobinemia can be increased when Axitinib is combined with Bupivacaine.]
[B03XA04, peginesatide, Levobupivacaine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, The risk or severity of methemoglobinemia can be increased when Azacitidine is combined with Bupivacaine.]
[L04AX01, azathioprine, The metabolism of Levobupivacaine can be decreased when combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of methemoglobinemia can be increased when Gemcitabine is combined with Bupivacaine.]
[J01CA09, azlocillin, The risk or severity of methemoglobinemia can be increased when Azlocillin is combined with Bupivacaine.]
[J01DF01, aztreonam, The risk or severity of methemoglobinemia can be increased when Aztreonam is combined with Bupivacaine.]
[R02AB04, bacitracin, The risk or severity of methemoglobinemia can be increased when Bacitracin is combined with Bupivacaine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Bupivacaine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Bupivacaine.]
[L01FD02, pertuzumab, The risk or severity of methemoglobinemia can be increased when Pertuzumab is combined with Bupivacaine.]
[A08AA11, lorcaserin, The metabolism of Bupivacaine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Bupivacaine can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The risk or severity of methemoglobinemia can be increased when Carfilzomib is combined with Bupivacaine.]
[V03AX03, cobicistat, The metabolism of Bupivacaine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Bupivacaine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Bupivacaine can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Bupivacaine.]
[L04AA31, teriflunomide, The serum concentration of Levobupivacaine can be decreased when it is combined with Teriflunomide.]
[L01EX05, regorafenib, The risk or severity of methemoglobinemia can be increased when Regorafenib is combined with Bupivacaine.]
[L01XL02, talimogene laherparepvec, The risk or severity of methemoglobinemia can be increased when Talimogene laherparepvec is combined with Bupivacaine.]
[N05CA04, barbital, The risk or severity of methemoglobinemia can be increased when Barbital is combined with Bupivacaine.]
[D02BA02, octinoxate, Levobupivacaine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Bupivacaine can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Bupivacaine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Bupivacaine.]
[C08CA13, lercanidipine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Bupivacaine can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Levobupivacaine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Diethyl ether.]
[L01EX07, cabozantinib, The risk or severity of methemoglobinemia can be increased when Cabozantinib is combined with Bupivacaine.]
[G04BE03, sildenafil, The metabolism of Bupivacaine can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Levobupivacaine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Bupivacaine.]
[A16AX08, teduglutide, Levobupivacaine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of methemoglobinemia can be increased when Bedaquiline is combined with Bupivacaine.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Bupivacaine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Bupivacaine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Bupivacaine.]
[G03XC05, ospemifene, The metabolism of Bupivacaine can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Benperidol.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of methemoglobinemia can be increased when Gemifloxacin is combined with Bupivacaine.]
[S01AE07, moxifloxacin, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Levobupivacaine.]
[A06AX06, tegaserod, The metabolism of Bupivacaine can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Benzocaine.]
[L03AA12, ancestim, Levobupivacaine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Bupivacaine can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Naratriptan.]
[L04AA18, everolimus, The risk or severity of methemoglobinemia can be increased when Everolimus is combined with Bupivacaine.]
[N04AC01, benztropine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Bupivacaine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EE01, trametinib, The risk or severity of methemoglobinemia can be increased when Trametinib is combined with Bupivacaine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Levobupivacaine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The risk or severity of methemoglobinemia can be increased when Afatinib is combined with Bupivacaine.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Levomilnacipran.]
[C08EA02, bepridil, The metabolism of Bupivacaine can be decreased when combined with Bepridil.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Riociguat.]
[A10BJ03, lixisenatide, Levobupivacaine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Bupivacaine may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Bupivacaine.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Bupivacaine.]
[J05AP05, simeprevir, The metabolism of Bupivacaine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Levobupivacaine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Bupivacaine.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapagliflozin.]
[C01CA27, droxidopa, Levobupivacaine may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The serum concentration of Bupivacaine can be increased when it is combined with Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Bupivacaine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Bupivacaine can be increased when combined with Apremilast.]
[P01CX04, miltefosine, The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Bupivacaine.]
[L02BG02, formestane, The risk or severity of methemoglobinemia can be increased when Formestane is combined with Bupivacaine.]
[S01ED02, betaxolol, The serum concentration of Bupivacaine can be increased when it is combined with Betaxolol.]
[V03AB34, fomepizole, Levobupivacaine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Bupivacaine may increase the hypotensive activities of Bethanidine.]
[L04AC11, siltuximab, The metabolism of Bupivacaine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Bupivacaine.]
[L01FG02, ramucirumab, The risk or severity of methemoglobinemia can be increased when Ramucirumab is combined with Bupivacaine.]
[J01XA04, dalbavancin, The risk or severity of methemoglobinemia can be increased when Dalbavancin is combined with Bupivacaine.]
[A03BA03, hyoscyamine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Levobupivacaine.]
[J01XX11, tedizolid, The risk or severity of methemoglobinemia can be increased when Tedizolid is combined with Bupivacaine.]
[L01XH04, belinostat, The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Bupivacaine.]
[L01EM01, idelalisib, The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Bupivacaine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Alfaxalone.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Empagliflozin.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[D11AA01, glycopyrronium, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05CM19, suvorexant, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Bupivacaine can be decreased when combined with Eliglustat.]
[L01FF02, pembrolizumab, The risk or severity of methemoglobinemia can be increased when Pembrolizumab is combined with Bupivacaine.]
[J01XA05, oritavancin, The risk or severity of methemoglobinemia can be increased when Oritavancin is combined with Bupivacaine.]
[S01AA15, dihydrostreptomycin, The risk or severity of methemoglobinemia can be increased when Dihydrostreptomycin is combined with Bupivacaine.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Acepromazine.]
[L01BC08, decitabine, The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Bupivacaine.]
[N04AA02, biperiden, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The risk or severity of methemoglobinemia can be increased when Pirfenidone is combined with Bupivacaine.]
[L01EX09, nintedanib, The risk or severity of methemoglobinemia can be increased when Nintedanib is combined with Bupivacaine.]
[S03AA06, gentamicin, The risk or severity of methemoglobinemia can be increased when Gentamicin is combined with Bupivacaine.]
[L01FX07, blinatumomab, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Bupivacaine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Bupivacaine.]
[L01XK01, olaparib, The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Bupivacaine.]
[L01FF01, nivolumab, The risk or severity of methemoglobinemia can be increased when Nivolumab is combined with Bupivacaine.]
[B01AF03, edoxaban, Levobupivacaine may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Bupivacaine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of methemoglobinemia can be increased when Palbociclib is combined with Bupivacaine.]
[L01EX08, lenvatinib, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Bupivacaine.]
[L01XH03, panobinostat, The metabolism of Bupivacaine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Bupivacaine.]
[L01DC01, bleomycin, The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Levobupivacaine.]
[A03AA09, difemerine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Bupivacaine can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Brexpiprazole.]
[L01XJ02, sonidegib, The risk or severity of methemoglobinemia can be increased when Sonidegib is combined with Bupivacaine.]
[A04AD14, rolapitant, The metabolism of Bupivacaine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Cariprazine.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[S01EC01, acetazolamide, The risk or severity of methemoglobinemia can be increased when Acetazolamide is combined with Bupivacaine.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Acetophenazine.]
[S02AA10, acetic acid, The risk or severity of methemoglobinemia can be increased when Acetic acid is combined with Bupivacaine.]
[A02BC03, lansoprazole, The metabolism of Bupivacaine can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Levobupivacaine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of methemoglobinemia can be increased when Trabectedin is combined with Bupivacaine.]
[J02AC05, isavuconazole, The metabolism of Bupivacaine can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The risk or severity of methemoglobinemia can be increased when Osimertinib is combined with Bupivacaine.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levobupivacaine.]
[L01FC01, daratumumab, The risk or severity of methemoglobinemia can be increased when Daratumumab is combined with Bupivacaine.]
[L01EE02, cobimetinib, The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Bupivacaine.]
[L01XG03, ixazomib, The risk or severity of methemoglobinemia can be increased when Ixazomib is combined with Bupivacaine.]
[L01FE03, necitumumab, The risk or severity of methemoglobinemia can be increased when Necitumumab is combined with Bupivacaine.]
[L01FX08, elotuzumab, The risk or severity of methemoglobinemia can be increased when Elotuzumab is combined with Bupivacaine.]
[L01ED03, alectinib, The risk or severity of methemoglobinemia can be increased when Alectinib is combined with Bupivacaine.]
[B01AC27, selexipag, Bupivacaine may increase the hypotensive activities of Selexipag.]
[M04AB05, lesinurad, Levobupivacaine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[L01XA04, satraplatin, The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Bupivacaine.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N03AX23, brivaracetam, The risk or severity of methemoglobinemia can be increased when Brivaracetam is combined with Bupivacaine.]
[L01XX52, venetoclax, The risk or severity of methemoglobinemia can be increased when Venetoclax is combined with Bupivacaine.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Levobupivacaine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Alverine.]
[R06AB01, brompheniramine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Amineptine.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Amlodipine.]
[L01FF05, atezolizumab, The risk or severity of methemoglobinemia can be increased when Atezolizumab is combined with Bupivacaine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Levobupivacaine can be decreased when combined with Obeticholic acid.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Bumetanide.]
[S01AA13, fusidic acid, The metabolism of Bupivacaine can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of methemoglobinemia can be increased when Pipemidic acid is combined with Bupivacaine.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Levobupivacaine.]
[C07AA19, bupranolol, The serum concentration of Bupivacaine can be increased when it is combined with Bupranolol.]
[N07BC01, buprenorphine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of methemoglobinemia can be increased when Buserelin is combined with Bupivacaine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Buspirone.]
[L01AB01, busulfan, The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Bupivacaine.]
[L01XX27, arsenic trioxide, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Bupivacaine.]
[P01BE02, artemether, The risk or severity of methemoglobinemia can be increased when Artemether is combined with Bupivacaine.]
[P01BE03, artesunate, The risk or severity of methemoglobinemia can be increased when Artesunate is combined with Bupivacaine.]
[M02AA03, clofezone, Levobupivacaine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of methemoglobinemia can be increased when Sparfloxacin is combined with Bupivacaine.]
[L01FX10, olaratumab, The risk or severity of methemoglobinemia can be increased when Olaratumab is combined with Bupivacaine.]
[S01GX07, azelastine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[J01CE04, azidocillin, The risk or severity of methemoglobinemia can be increased when Azidocillin is combined with Bupivacaine.]
[L01XK03, rucaparib, The metabolism of Bupivacaine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of methemoglobinemia can be increased when Azithromycin is combined with Bupivacaine.]
[J01CA06, bacampicillin, The risk or severity of methemoglobinemia can be increased when Bacampicillin is combined with Bupivacaine.]
[L01EF02, ribociclib, The metabolism of Bupivacaine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Levobupivacaine.]
[L01FF04, avelumab, The risk or severity of methemoglobinemia can be increased when Avelumab is combined with Bupivacaine.]
[A06AH05, naldemedine, Levobupivacaine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Bupivacaine.]
[N02BF02, pregabalin, The therapeutic efficacy of Levobupivacaine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of methemoglobinemia can be increased when Beclamide is combined with Bupivacaine.]
[N06BC01, caffeine, The metabolism of Levobupivacaine can be decreased when combined with Caffeine.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Benazepril.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Levobupivacaine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of methemoglobinemia can be increased when Linezolid is combined with Bupivacaine.]
[J05AF06, abacavir, Levobupivacaine may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Bupivacaine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Bupivacaine.]
[L01XK02, niraparib, The risk or severity of methemoglobinemia can be increased when Niraparib is combined with Bupivacaine.]
[L04AB02, infliximab, The metabolism of Levobupivacaine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Bupivacaine can be decreased when combined with Midostaurin.]
[L01FF03, durvalumab, The risk or severity of methemoglobinemia can be increased when Durvalumab is combined with Bupivacaine.]
[L01ED04, brigatinib, The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Bupivacaine.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Bupivacaine.]
[P01AX10, fumagillin, The risk or severity of methemoglobinemia can be increased when Fumagillin is combined with Bupivacaine.]
[J01MA23, delafloxacin, The risk or severity of methemoglobinemia can be increased when Delafloxacin is combined with Bupivacaine.]
[L01BC06, capecitabine, The risk or severity of methemoglobinemia can be increased when Capecitabine is combined with Bupivacaine.]
[L01XX59, enasidenib, The risk or severity of methemoglobinemia can be increased when Enasidenib is combined with Bupivacaine.]
[L01EH02, neratinib, The risk or severity of methemoglobinemia can be increased when Neratinib is combined with Bupivacaine.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Bupivacaine.]
[L01XH01, vorinostat, The risk or severity of methemoglobinemia can be increased when Vorinostat is combined with Bupivacaine.]
[L01EM02, copanlisib, The risk or severity of methemoglobinemia can be increased when Copanlisib is combined with Bupivacaine.]
[L01EF03, abemaciclib, The risk or severity of methemoglobinemia can be increased when Abemaciclib is combined with Bupivacaine.]
[C07AB07, bisoprolol, The serum concentration of Bupivacaine can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Bupivacaine can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, The risk or severity of methemoglobinemia can be increased when Cefprozil is combined with Bupivacaine.]
[C07AA17, bopindolol, The serum concentration of Bupivacaine can be increased when it is combined with Bopindolol.]
[N04AA11, bornaprine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[L01BA03, raltitrexed, The risk or severity of methemoglobinemia can be increased when Raltitrexed is combined with Bupivacaine.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nesiritide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Levobupivacaine may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01XL04, tisagenlecleucel, The risk or severity of methemoglobinemia can be increased when Tisagenlecleucel is combined with Bupivacaine.]
[L01XL03, axicabtagene ciloleucel, The risk or severity of methemoglobinemia can be increased when Axicabtagene ciloleucel is combined with Bupivacaine.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Bupivacaine.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Butriptyline.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Vinylbital.]
[R06AX18, acrivastine, Levobupivacaine may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Captopril.]
[L02BB05, apalutamide, The risk or severity of methemoglobinemia can be increased when Apalutamide is combined with Bupivacaine.]
[N03AF01, carbamazepine, The risk or severity of methemoglobinemia can be increased when Carbamazepine is combined with Bupivacaine.]
[A03AA03, camylofine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[J01CA03, carbenicillin, The risk or severity of methemoglobinemia can be increased when Carbenicillin is combined with Bupivacaine.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The metabolism of Levobupivacaine can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The serum concentration of Bupivacaine can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Bupivacaine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Bupivacaine.]
[L04AA37, baricitinib, Levobupivacaine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, The risk or severity of methemoglobinemia can be increased when Cefepime is combined with Bupivacaine.]
[J01DD10, cefetamet, The risk or severity of methemoglobinemia can be increased when Cefetamet is combined with Bupivacaine.]
[J01DD09, cefodizime, The risk or severity of methemoglobinemia can be increased when Cefodizime is combined with Bupivacaine.]
[J01DC11, ceforanide, The risk or severity of methemoglobinemia can be increased when Ceforanide is combined with Bupivacaine.]
[J01DD13, cefpodoxime, The risk or severity of methemoglobinemia can be increased when Cefpodoxime is combined with Bupivacaine.]
[L01EC03, encorafenib, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Bupivacaine.]
[L01EE03, binimetinib, The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Bupivacaine.]
[J01DD14, ceftibuten, The risk or severity of methemoglobinemia can be increased when Ceftibuten is combined with Bupivacaine.]
[J01GB14, plazomicin, The risk or severity of methemoglobinemia can be increased when Plazomicin is combined with Bupivacaine.]
[C07AB08, celiprolol, The serum concentration of Bupivacaine can be increased when it is combined with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Bupivacaine.]
[L01XX62, ivosidenib, The metabolism of Bupivacaine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The risk or severity of methemoglobinemia can be increased when Tafenoquine is combined with Bupivacaine.]
[L01FX09, mogamulizumab, The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Bupivacaine.]
[A16AX14, migalastat, Levobupivacaine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Bupivacaine can be decreased when combined with Stiripentol.]
[J01AA13, eravacycline, The risk or severity of methemoglobinemia can be increased when Eravacycline is combined with Bupivacaine.]
[L01EM04, duvelisib, The risk or severity of methemoglobinemia can be increased when Duvelisib is combined with Bupivacaine.]
[L01FF06, cemiplimab, The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Bupivacaine.]
[L01EB07, dacomitinib, The risk or severity of methemoglobinemia can be increased when Dacomitinib is combined with Bupivacaine.]
[J01AA14, sarecycline, The risk or severity of methemoglobinemia can be increased when Sarecycline is combined with Bupivacaine.]
[J01AA15, omadacycline, The risk or severity of methemoglobinemia can be increased when Omadacycline is combined with Bupivacaine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Cetirizine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Levobupivacaine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Levobupivacaine.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01FB02, moxetumomab pasudotox, The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Bupivacaine.]
[L01XK04, talazoparib, The risk or severity of methemoglobinemia can be increased when Talazoparib is combined with Bupivacaine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Bupivacaine.]
[R03BB08, revefenacin, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The risk or severity of methemoglobinemia can be increased when Lorlatinib is combined with Bupivacaine.]
[L04AA39, emapalumab, The metabolism of Bupivacaine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Levobupivacaine.]
[L01EX12, larotrectinib, The risk or severity of methemoglobinemia can be increased when Larotrectinib is combined with Bupivacaine.]
[L01EX13, gilteritinib, The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Bupivacaine.]
[L01XJ03, glasdegib, The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Bupivacaine.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Bupivacaine is combined with Amifampridine.]
[A06AX05, prucalopride, Levobupivacaine may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[L01XX67, tagraxofusp, The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Bupivacaine.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Bupivacaine.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Bupivacaine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Bupivacaine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of methemoglobinemia can be increased when Brexanolone is combined with Bupivacaine.]
[L01EN01, erdafitinib, The risk or severity of methemoglobinemia can be increased when Erdafitinib is combined with Bupivacaine.]
[N05BA09, clobazam, The metabolism of Bupivacaine can be decreased when combined with Clobazam.]
[J01AA11, clomocycline, The risk or severity of methemoglobinemia can be increased when Clomocycline is combined with Bupivacaine.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Cloxazolam.]
[C09CA06, candesartan, Bupivacaine may increase the hypotensive activities of Candesartan.]
[L01XX29, denileukin diftitox, The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Bupivacaine.]
[L04AB01, etanercept, The metabolism of Levobupivacaine can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The risk or severity of methemoglobinemia can be increased when Alpelisib is combined with Bupivacaine.]
[L01FX14, polatuzumab vedotin, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Bupivacaine.]
[J01DC04, cefaclor, The risk or severity of methemoglobinemia can be increased when Cefaclor is combined with Bupivacaine.]
[J01DB05, cefadroxil, The risk or severity of methemoglobinemia can be increased when Cefadroxil is combined with Bupivacaine.]
[J01DC03, cefamandole, The risk or severity of methemoglobinemia can be increased when Cefamandole is combined with Bupivacaine.]
[L01XX66, selinexor, The risk or severity of methemoglobinemia can be increased when Selinexor is combined with Bupivacaine.]
[J01DB07, cefatrizine, The risk or severity of methemoglobinemia can be increased when Cefatrizine is combined with Bupivacaine.]
[J01DB04, cefazolin, The risk or severity of methemoglobinemia can be increased when Cefazolin is combined with Bupivacaine.]
[L02BB06, darolutamide, The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Bupivacaine.]
[J01CF03, methicillin, The risk or severity of methemoglobinemia can be increased when Meticillin is combined with Bupivacaine.]
[J01DC09, cefmetazole, The risk or severity of methemoglobinemia can be increased when Cefmetazole is combined with Levobupivacaine.]
[J01DC06, cefonicid, The risk or severity of methemoglobinemia can be increased when Cefonicid is combined with Bupivacaine.]
[L01EX15, pexidartinib, The risk or severity of methemoglobinemia can be increased when Pexidartinib is combined with Bupivacaine.]
[J01DD12, cefoperazone, The risk or severity of methemoglobinemia can be increased when Cefoperazone is combined with Bupivacaine.]
[J01DD01, cefotaxime, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Bupivacaine.]
[J01DC05, cefotetan, The risk or severity of methemoglobinemia can be increased when Cefotetan is combined with Bupivacaine.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyamemazine.]
[J01DC07, cefotiam, The risk or severity of methemoglobinemia can be increased when Cefotiam is combined with Levobupivacaine.]
[J01DC01, cefoxitin, The risk or severity of methemoglobinemia can be increased when Cefoxitin is combined with Bupivacaine.]
[J01DD03, cefsulodin, The risk or severity of methemoglobinemia can be increased when Cefsulodin is combined with Bupivacaine.]
[J01DD02, ceftazidime, The risk or severity of methemoglobinemia can be increased when Ceftazidime is combined with Bupivacaine.]
[C03BX03, cicletanine, Bupivacaine may increase the hypotensive activities of Cicletanine.]
[J01DD07, ceftizoxime, The risk or severity of methemoglobinemia can be increased when Ceftizoxime is combined with Bupivacaine.]
[J01DD04, ceftriaxone, The risk or severity of methemoglobinemia can be increased when Ceftriaxone is combined with Bupivacaine.]
[S01AA27, cefuroxime, The risk or severity of methemoglobinemia can be increased when Cefuroxime is combined with Bupivacaine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Bupivacaine.]
[L01EJ02, fedratinib, The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Bupivacaine.]
[L01EX14, entrectinib, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Bupivacaine.]
[N07XX11, pitolisant, The serum concentration of Bupivacaine can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, The risk or severity of methemoglobinemia can be increased when Lefamulin is combined with Bupivacaine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Bupivacaine.]
[C03AA09, cyclothiazide, Bupivacaine may increase the hypotensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The metabolism of Levobupivacaine can be increased when combined with Insulin pork.]
[J01XX09, daptomycin, The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Levobupivacaine.]
[J01DB01, cephalexin, The risk or severity of methemoglobinemia can be increased when Cephalexin is combined with Bupivacaine.]
[J01DB02, cephaloridine, The risk or severity of methemoglobinemia can be increased when Cefaloridine is combined with Bupivacaine.]
[J01DB03, cephalothin, The risk or severity of methemoglobinemia can be increased when Cefalotin is combined with Bupivacaine.]
[J01DB08, cephapirin, The risk or severity of methemoglobinemia can be increased when Cefapirin is combined with Bupivacaine.]
[J01DB09, cephradine, The risk or severity of methemoglobinemia can be increased when Cefradine is combined with Bupivacaine.]
[L01FD01, trastuzumab, The risk or severity of methemoglobinemia can be increased when Trastuzumab is combined with Bupivacaine.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of methemoglobinemia can be increased when Trastuzumab deruxtecan is combined with Bupivacaine.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Bupivacaine.]
[L01EL03, zanubrutinib, The risk or severity of methemoglobinemia can be increased when Zanubrutinib is combined with Bupivacaine.]
[N03AX25, cenobamate, The serum concentration of Bupivacaine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Bupivacaine can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Levobupivacaine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[L01FX13, enfortumab vedotin, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Bupivacaine.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The metabolism of Bupivacaine can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Levobupivacaine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dezocine.]
[L01XX10, masoprocol, The risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Bupivacaine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Bupivacaine can be decreased when combined with Diacerein.]
[L01FC02, isatuximab, The risk or severity of methemoglobinemia can be increased when Isatuximab is combined with Bupivacaine.]
[S01AE06, gatifloxacin, The risk or severity of methemoglobinemia can be increased when Gatifloxacin is combined with Bupivacaine.]
[H02CA02, osilodrostat, The metabolism of Bupivacaine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Bupivacaine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The risk or severity of methemoglobinemia can be increased when Selumetinib is combined with Bupivacaine.]
[R02AA03, dichlorobenzyl alcohol, Levobupivacaine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The risk or severity of methemoglobinemia can be increased when Dienogest is combined with Bupivacaine.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Difenoxin.]
[L01XD01, porfimer sodium, The risk or severity of methemoglobinemia can be increased when Porfimer sodium is combined with Bupivacaine.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Bupivacaine.]
[M01AH02, rofecoxib, The metabolism of Levobupivacaine can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Bupivacaine.]
[C08CA16, clevidipine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Bupivacaine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of methemoglobinemia can be increased when Valpromide is combined with Bupivacaine.]
[J01FA13, dirithromycin, The risk or severity of methemoglobinemia can be increased when Dirithromycin is combined with Bupivacaine.]
[L01AA02, chlorambucil, The risk or severity of methemoglobinemia can be increased when Chlorambucil is combined with Bupivacaine.]
[S03AA08, chloramphenicol, The risk or severity of methemoglobinemia can be increased when Chloramphenicol is combined with Bupivacaine.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlordiazepoxide.]
[C02AA06, methoserpidine, Bupivacaine may increase the hypotensive activities of Methoserpidine.]
[L01EN02, pemigatinib, The risk or severity of methemoglobinemia can be increased when Pemigatinib is combined with Bupivacaine.]
[L01FX17, sacituzumab govitecan, The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Bupivacaine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Bupivacaine.]
[A03AA08, dihexyverine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Bupivacaine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Opicapone.]
[P01BE01, artemisinin, The risk or severity of methemoglobinemia can be increased when Artemisinin is combined with Bupivacaine.]
[G04BD09, trospium, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EX19, ripretinib, The risk or severity of methemoglobinemia can be increased when Ripretinib is combined with Bupivacaine.]
[V08CA05, mangafodipir, Levobupivacaine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The risk or severity of methemoglobinemia can be increased when Selpercatinib is combined with Bupivacaine.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05CM02, chlormethiazole, The risk or severity of methemoglobinemia can be increased when Clomethiazole is combined with Bupivacaine.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Dyclonine.]
[L01XX69, lurbinectedin, The risk or severity of methemoglobinemia can be increased when Lurbinectedin is combined with Bupivacaine.]
[C08CA17, levamlodipine, Bupivacaine may increase the hypotensive activities of Levamlodipine.]
[P01BB01, proguanil, The risk or severity of methemoglobinemia can be increased when Proguanil is combined with Bupivacaine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Bupivacaine is combined with Remimazolam.]
[L01FX12, tafasitamab, The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Bupivacaine.]
[L01XL06, brexucabtagene autoleucel, The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Bupivacaine.]
[N07XX04, sodium oxybate, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sodium oxybate.]
[L01DB04, aclarubicin, The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Bupivacaine.]
[L04AC19, satralizumab, The serum concentration of Bupivacaine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Bupivacaine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Bupivacaine can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Bupivacaine.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorothiazide.]
[G03CA06, chlorotrianisene, The risk or severity of methemoglobinemia can be increased when Chlorotrianisene is combined with Bupivacaine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Bupivacaine can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05AF03, chlorprothixene, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[S01AA02, chlortetracycline, The risk or severity of methemoglobinemia can be increased when Chlortetracycline is combined with Bupivacaine.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The metabolism of Bupivacaine can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Etifoxine.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N02BA03, choline salicylate, Levobupivacaine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of methemoglobinemia can be increased when Vinpocetine is combined with Bupivacaine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethyl loflazepate.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[B06AC06, berotralstat, The metabolism of Bupivacaine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Bupivacaine can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of methemoglobinemia can be increased when Fludarabine is combined with Bupivacaine.]
[M01AX25, chondroitin sulfates, Levobupivacaine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FD06, margetuximab, The risk or severity of methemoglobinemia can be increased when Margetuximab is combined with Bupivacaine.]
[P03AX07, abametapir, The serum concentration of Bupivacaine can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Vericiguat.]
[L01EX21, tepotinib, The risk or severity of methemoglobinemia can be increased when Tepotinib is combined with Bupivacaine.]
[L01EX25, umbralisib, The risk or severity of methemoglobinemia can be increased when Umbralisib is combined with Bupivacaine.]
[V03AF12, trilaciclib, The metabolism of Levobupivacaine can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of methemoglobinemia can be increased when Felbamate is combined with Bupivacaine.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Levobupivacaine.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Fenoldopam.]
[J01DD08, cefixime, The risk or severity of methemoglobinemia can be increased when Cefixime is combined with Bupivacaine.]
[J01DD15, cefdinir, The risk or severity of methemoglobinemia can be increased when Cefdinir is combined with Bupivacaine.]
[J01MB07, flumequine, The risk or severity of methemoglobinemia can be increased when Flumequine is combined with Bupivacaine.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N02BG07, flupirtine, Levobupivacaine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Bupivacaine.]
[S01LA08, bevacizumab, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Bupivacaine.]
[L01EK03, tivozanib, The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Bupivacaine.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Levobupivacaine can be increased when it is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Bupivacaine may increase the hypotensive activities of Dasiglucagon.]
[L01XL07, idecabtagene vicleucel, The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Bupivacaine.]
[L01FF07, dostarlimab, The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Bupivacaine.]
[L01FX22, loncastuximab tesirine, The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Bupivacaine.]
[A02BA01, cimetidine, The metabolism of Bupivacaine can be decreased when combined with Cimetidine.]
[R02AB03, fusafungin, The risk or severity of methemoglobinemia can be increased when Fusafungine is combined with Bupivacaine.]
[N02BF01, gabapentin, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Bupivacaine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Bupivacaine.]
[J01MB06, cinoxacin, The risk or severity of methemoglobinemia can be increased when Cinoxacin is combined with Bupivacaine.]
[L01XX73, sotorasib, The serum concentration of Bupivacaine can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Bupivacaine.]
[S03AA07, ciprofloxacin, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Bupivacaine.]
[L01XA01, cisplatin, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Bupivacaine.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Levobupivacaine can be increased when combined with Somapacitan.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Bupivacaine.]
[L01XX74, belzutifan, The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Bupivacaine.]
[H01AC09, lonapegsomatropin, The metabolism of Levobupivacaine can be increased when combined with Lonapegsomatropin.]
[L01FX23, tisotumab vedotin, The risk or severity of methemoglobinemia can be increased when Tisotumab vedotin is combined with Bupivacaine.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Levobupivacaine.]
[M01AG01, mefenamic acid, The metabolism of Levobupivacaine can be decreased when combined with Mefenamic acid.]
[J01FF01, clindamycin, The risk or severity of methemoglobinemia can be increased when Clindamycin is combined with Bupivacaine.]
[N06AX25, St. John's wort extract, The metabolism of Bupivacaine can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The risk or severity of methemoglobinemia can be increased when Asciminib is combined with Bupivacaine.]
[L02BG06, exemestane, The risk or severity of methemoglobinemia can be increased when Exemestane is combined with Bupivacaine.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Bupivacaine.]
[L01XX75, tebentafusp, The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Bupivacaine.]
[J04BA01, clofazimine, The risk or severity of methemoglobinemia can be increased when Clofazimine is combined with Bupivacaine.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The metabolism of Levobupivacaine can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Bupivacaine.]
[N03AE01, clonazepam, The risk or severity of methemoglobinemia can be increased when Clonazepam is combined with Bupivacaine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Bupivacaine.]
[C01EB24, mavacamten, The serum concentration of Bupivacaine can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01FX20, tremelimumab, The risk or severity of methemoglobinemia can be increased when Tremelimumab is combined with Bupivacaine.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Granisetron.]
[J01CF02, cloxacillin, The risk or severity of methemoglobinemia can be increased when Cloxacillin is combined with Bupivacaine.]
[L01XX77, adagrasib, The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Bupivacaine.]
[N05AH02, clozapine, The metabolism of Bupivacaine can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The risk or severity of methemoglobinemia can be increased when Futibatinib is combined with Bupivacaine.]
[L01FE02, panitumumab, The risk or severity of methemoglobinemia can be increased when Panitumumab is combined with Bupivacaine.]
[J01GB12, arbekacin, The risk or severity of methemoglobinemia can be increased when Arbekacin is combined with Bupivacaine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Halazepam.]
[L01EX11, quizartinib, The risk or severity of methemoglobinemia can be increased when Quizartinib is combined with Bupivacaine.]
[H01AC08, somatrogon, The metabolism of Bupivacaine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Cocaine.]
[C02KB01, metyrosine, Bupivacaine may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Bupivacaine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Codeine.]
[J01CA18, hetacillin, The risk or severity of methemoglobinemia can be increased when Hetacillin is combined with Bupivacaine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Hexafluronium.]
[M04AC01, colchicine, Levobupivacaine may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[J01XX04, spectinomycin, The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Bupivacaine.]
[A03BB06, homatropine methylbromide, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, The risk or severity of methemoglobinemia can be increased when Colistin is combined with Bupivacaine.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of methemoglobinemia can be increased when Omacetaxine mepesuccinate is combined with Bupivacaine.]
[J01DE02, cefpirome, The risk or severity of methemoglobinemia can be increased when Cefpirome is combined with Bupivacaine.]
[L04AA13, leflunomide, The serum concentration of Levobupivacaine can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of methemoglobinemia can be increased when Ifenprodil is combined with Bupivacaine.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Bupivacaine.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01BB07, nelarabine, The risk or severity of methemoglobinemia can be increased when Nelarabine is combined with Bupivacaine.]
[J01FA15, telithromycin, The metabolism of Bupivacaine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Bupivacaine.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Desloratadine.]
[J05AB14, valganciclovir, Levobupivacaine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Levobupivacaine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Levobupivacaine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Levobupivacaine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Levobupivacaine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Levobupivacaine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[A03AX10, isometheptene, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Almotriptan.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[J02AC02, itraconazole, The metabolism of Bupivacaine can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The metabolism of Levobupivacaine can be decreased when combined with Acyclovir.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketazolam.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L02BA03, fulvestrant, The risk or severity of methemoglobinemia can be increased when Fulvestrant is combined with Bupivacaine.]
[L01EA01, imatinib, The serum concentration of Bupivacaine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Bupivacaine can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Bupivacaine may increase the hypotensive activities of Lacidipine.]
[V03AF07, rasburicase, The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Bupivacaine.]
[N03AX09, lamotrigine, The risk or severity of methemoglobinemia can be increased when Lamotrigine is combined with Bupivacaine.]
[N07BC04, lofexidine, The therapeutic efficacy of Bupivacaine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of methemoglobinemia can be increased when Lomefloxacin is combined with Bupivacaine.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lormetazepam.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[J01DC08, loracarbef, The risk or severity of methemoglobinemia can be increased when Loracarbef is combined with Bupivacaine.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lisinopril.]
[A06AD01, magnesium carbonate, Levobupivacaine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Bupivacaine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[D10AF04, meclocycline, The risk or severity of methemoglobinemia can be increased when Meclocycline is combined with Bupivacaine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Medifoxamine.]
[C07AA14, mepindolol, The serum concentration of Bupivacaine can be increased when it is combined with Mepindolol.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Bupivacaine.]
[J01DH02, meropenem, The risk or severity of methemoglobinemia can be increased when Meropenem is combined with Bupivacaine.]
[J01CA14, methampicillin, The risk or severity of methemoglobinemia can be increased when Metampicillin is combined with Bupivacaine.]
[N04AA03, methixene, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Cyclobarbital.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Melperone.]
[S01AA22, micronomicin, The risk or severity of methemoglobinemia can be increased when Micronomicin is combined with Bupivacaine.]
[C03AA07, cyclopenthiazide, Bupivacaine may increase the hypotensive activities of Cyclopenthiazide.]
[J01FA03, midecamycin, The risk or severity of methemoglobinemia can be increased when Midecamycin is combined with Bupivacaine.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Bupivacaine.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Bupivacaine.]
[J04AB01, cycloserine, The risk or severity of methemoglobinemia can be increased when Cycloserine is combined with Bupivacaine.]
[S01XA18, cyclosporine, The metabolism of Bupivacaine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Bupivacaine.]
[N06BA07, modafinil, The metabolism of Levobupivacaine can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Moexipril.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Bupivacaine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Moxonidine.]
[L01BC01, cytarabine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Bupivacaine.]
[J05AF10, entecavir, The metabolism of Levobupivacaine can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Bupivacaine.]
[M01AH05, etoricoxib, The metabolism of Bupivacaine can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Bupivacaine.]
[L01DA01, dactinomycin, The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Bupivacaine.]
[G03XA01, danazol, The metabolism of Bupivacaine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dantrolene.]
[J04BA02, dapsone, The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Bupivacaine.]
[L01DB02, daunorubicin, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Bupivacaine.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Deanol.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Bupivacaine.]
[L01DB09, valrubicin, The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Bupivacaine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.]
[M01AX01, nabumetone, The metabolism of Levobupivacaine can be decreased when combined with Nabumetone.]
[N07BB05, nalmefene, Levobupivacaine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[J01AA01, demeclocycline, The risk or severity of methemoglobinemia can be increased when Demeclocycline is combined with Bupivacaine.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nordazepam.]
[C07AB12, nebivolol, The serum concentration of Bupivacaine can be increased when it is combined with Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Bupivacaine can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Bupivacaine.]
[L02BB02, nilutamide, The risk or severity of methemoglobinemia can be increased when Nilutamide is combined with Bupivacaine.]
[L01FE01, cetuximab, The risk or severity of methemoglobinemia can be increased when Cetuximab is combined with Bupivacaine.]
[N03AG06, tiagabine, The risk or severity of methemoglobinemia can be increased when Tiagabine is combined with Bupivacaine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Levobupivacaine.]
[M03AC11, cisatracurium, Bupivacaine may increase the neuromuscular blocking activities of Cisatracurium.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AB10, escitalopram, The serum concentration of Bupivacaine can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[R02AA02, dequalinium, The risk or severity of methemoglobinemia can be increased when Dequalinium is combined with Bupivacaine.]
[A07EC03, olsalazine, Olsalazine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AA01, desipramine, The metabolism of Bupivacaine can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[V04CH02, indigo carmine, Levobupivacaine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, The risk or severity of methemoglobinemia can be increased when Ertapenem is combined with Bupivacaine.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Bupivacaine.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N03AF02, oxcarbazepine, The risk or severity of methemoglobinemia can be increased when Oxcarbazepine is combined with Bupivacaine.]
[S03BA01, dexamethasone, The risk or severity of methemoglobinemia can be increased when Dexamethasone is combined with Bupivacaine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxiracetam.]
[N04AA08, dexetimide, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Bupivacaine can be decreased when combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Levobupivacaine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Bupivacaine.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of methemoglobinemia can be increased when Paramethadione is combined with Bupivacaine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dextromoramide.]
[N06AB05, paroxetine, The metabolism of Bupivacaine can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Levobupivacaine can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Levobupivacaine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Levobupivacaine.]
[P03AC04, permethrin, Levobupivacaine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of methemoglobinemia can be increased when Diazepam is combined with Bupivacaine.]
[N03AX07, phenacemide, The risk or severity of methemoglobinemia can be increased when Phenacemide is combined with Bupivacaine.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Diazoxide.]
[J01CE05, phenethicillin, The risk or severity of methemoglobinemia can be increased when Pheneticillin is combined with Bupivacaine.]
[S01AA29, dibekacin, The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Bupivacaine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of methemoglobinemia can be increased when Phensuximide is combined with Bupivacaine.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Cinchocaine.]
[R05DA08, pholcodine, Levobupivacaine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Levobupivacaine can be decreased when combined with Diclofenac.]
[J01CF01, dicloxacillin, The risk or severity of methemoglobinemia can be increased when Dicloxacillin is combined with Bupivacaine.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[A03AA07, dicyclomine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C02DG01, pinacidil, Bupivacaine may increase the hypotensive activities of Pinacidil.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Pipamperone.]
[A03AB14, pipenzolate, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The risk or severity of methemoglobinemia can be increased when Ixabepilone is combined with Bupivacaine.]
[L01EB02, erlotinib, The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Bupivacaine.]
[L01DB08, pirarubicin, The risk or severity of methemoglobinemia can be increased when Pirarubicin is combined with Bupivacaine.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of adverse effects can be increased when Isradipine is combined with Levobupivacaine.]
[D07XC04, diflucortolone, Levobupivacaine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, Diflunisal may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C01AA05, digoxin, Levobupivacaine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Bupivacaine may increase the hypotensive activities of Dihydralazine.]
[L01XX24, pegaspargase, The risk or severity of methemoglobinemia can be increased when Pegaspargase is combined with Bupivacaine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydromorphone.]
[L04AX04, lenalidomide, The risk or severity of methemoglobinemia can be increased when Lenalidomide is combined with Bupivacaine.]
[J05AE08, atazanavir, The metabolism of Bupivacaine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Bupivacaine may increase the hypotensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, Levobupivacaine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Bupivacaine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Levobupivacaine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Pridinol.]
[R06AB03, dimethindene, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Bupivacaine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of methemoglobinemia can be increased when Progabide is combined with Bupivacaine.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Levobupivacaine.]
[J01CE03, propicillin, The risk or severity of methemoglobinemia can be increased when Propicillin is combined with Bupivacaine.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Levobupivacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Quazepam.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Bupivacaine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Bupivacaine.]
[S01XA23, sirolimus, The risk or severity of methemoglobinemia can be increased when Sirolimus is combined with Bupivacaine.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Remoxipride.]
[S01AX06, resorcinol, Levobupivacaine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The risk or severity of methemoglobinemia can be increased when Rifamycin is combined with Bupivacaine.]
[J04AB05, rifapentine, The risk or severity of methemoglobinemia can be increased when Rifapentine is combined with Bupivacaine.]
[D06AX11, rifaximin, The risk or severity of methemoglobinemia can be increased when Rifaximin is combined with Bupivacaine.]
[N07XX02, riluzole, The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Bupivacaine.]
[N05AX08, risperidone, Bupivacaine may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Ropivacaine is combined with Bupivacaine.]
[J01MB01, rosoxacin, The risk or severity of methemoglobinemia can be increased when Rosoxacin is combined with Bupivacaine.]
[L01EX01, sunitinib, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Bupivacaine.]
[A04AD12, aprepitant, The metabolism of Bupivacaine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Bupivacaine.]
[G04BE08, tadalafil, Bupivacaine may increase the hypotensive activities of Tadalafil.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C02KX02, ambrisentan, Bupivacaine may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Bupivacaine.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AA16, dothiepin, The metabolism of Bupivacaine can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The risk or severity of methemoglobinemia can be increased when Doxorubicin is combined with Bupivacaine.]
[J01AA02, doxycycline, The risk or severity of methemoglobinemia can be increased when Doxycycline is combined with Levobupivacaine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Bupivacaine.]
[A12CA02, sodium sulfate, Levobupivacaine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Bupivacaine may increase the hypotensive activities of Spirapril.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sumatriptan.]
[V04CX07, edrophonium, Levobupivacaine may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The serum concentration of Bupivacaine can be increased when it is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of methemoglobinemia can be increased when Temafloxacin is combined with Bupivacaine.]
[J01CA17, temocillin, The risk or severity of methemoglobinemia can be increased when Temocillin is combined with Bupivacaine.]
[L01AX03, temozolomide, The risk or severity of methemoglobinemia can be increased when Temozolomide is combined with Bupivacaine.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Terazosin.]
[D01BA02, terbinafine, The metabolism of Bupivacaine can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The serum concentration of Bupivacaine can be increased when it is combined with Tertatolol.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiopropazate.]
[G04BD01, emepronium, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Bupivacaine.]
[N06BA09, atomoxetine, Atomoxetine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N03AX11, topiramate, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Levobupivacaine.]
[L02BA02, toremifene, The risk or severity of methemoglobinemia can be increased when Toremifene is combined with Bupivacaine.]
[C03CA04, torsemide, The risk or severity of adverse effects can be increased when Torasemide is combined with Bupivacaine.]
[J01AA12, tigecycline, The risk or severity of methemoglobinemia can be increased when Tigecycline is combined with Bupivacaine.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Trandolapril.]
[L01AB02, treosulfan, The risk or severity of methemoglobinemia can be increased when Treosulfan is combined with Bupivacaine.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Triclofos.]
[A03AB08, tridihexethyl, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[H02CA01, trilostane, The risk or severity of methemoglobinemia can be increased when Trilostane is combined with Bupivacaine.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Trimethobenzamide.]
[L02AE04, triptorelin, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Bupivacaine.]
[L01AA07, trofosfamide, The risk or severity of methemoglobinemia can be increased when Trofosfamide is combined with Bupivacaine.]
[N04AA12, tropatepine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Bupivacaine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Urapidil.]
[J01MA04, enoxacin, The risk or severity of methemoglobinemia can be increased when Enoxacin is combined with Bupivacaine.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Veralipride.]
[L01CA04, vinorelbine, The risk or severity of methemoglobinemia can be increased when Vinorelbine is combined with Bupivacaine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Bupivacaine can be decreased when combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Bupivacaine can be decreased when combined with Barnidipine.]
[L01DB03, epirubicin, The risk or severity of methemoglobinemia can be increased when Epirubicin is combined with Bupivacaine.]
[C09AA15, zofenopril, Bupivacaine may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N03AX15, zonisamide, The risk or severity of methemoglobinemia can be increased when Zonisamide is combined with Bupivacaine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Zotepine.]
[L01XA02, carboplatin, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Bupivacaine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Guanfacine.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Iloprost.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Bupivacaine can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Levobupivacaine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Bupivacaine.]
[N05CD04, estazolam, The risk or severity of methemoglobinemia can be increased when Estazolam is combined with Bupivacaine.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Bupivacaine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Levobupivacaine can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Bupivacaine.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Levobupivacaine can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The risk or severity of methemoglobinemia can be increased when Ethambutol is combined with Bupivacaine.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Bupivacaine.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bupivacaine.]
[L02AA03, ethinyl estradiol, The metabolism of Levobupivacaine can be decreased when combined with Ethinylestradiol.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Amifostine.]
[J04AD03, ethionamide, The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Bupivacaine.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01AG01, ethoglucid, The risk or severity of methemoglobinemia can be increased when Etoglucid is combined with Bupivacaine.]
[N04AA05, profenamine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of methemoglobinemia can be increased when Ethosuximide is combined with Bupivacaine.]
[N03AB01, ethotoin, The risk or severity of methemoglobinemia can be increased when Ethotoin is combined with Bupivacaine.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Ethyl chloride.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Levobupivacaine.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Levobupivacaine.]
[L01CB01, etoposide, The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Bupivacaine.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sertindole.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[J01MA08, fleroxacin, The risk or severity of methemoglobinemia can be increased when Fleroxacin is combined with Bupivacaine.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Bupivacaine.]
[R06AX12, terfenadine, The metabolism of Bupivacaine can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, The risk or severity of methemoglobinemia can be increased when Trimetrexate is combined with Bupivacaine.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Bupivacaine.]
[N06AB08, fluvoxamine, The metabolism of Bupivacaine can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Levobupivacaine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Bupivacaine.]
[R01AX06, mupirocin, The risk or severity of methemoglobinemia can be increased when Mupirocin is combined with Bupivacaine.]
[L02AE02, leuprolide, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Levobupivacaine.]
[M01CB01, gold sodium thiomalate, Levobupivacaine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Levobupivacaine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[A02BA03, famotidine, The metabolism of Levobupivacaine can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[P02CA03, albendazole, The metabolism of Levobupivacaine can be increased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Bupivacaine can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The risk or severity of methemoglobinemia can be increased when Fenfluramine is combined with Bupivacaine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Fentanyl.]
[R03CC02, albuterol, Salbutamol may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01BB06, clofarabine, The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Bupivacaine.]
[L04AA40, cladribine, The risk or severity of methemoglobinemia can be increased when Cladribine is combined with Bupivacaine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[G04BD02, flavoxate, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Bupivacaine.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[J01CF05, floxacillin, The risk or severity of methemoglobinemia can be increased when Flucloxacillin is combined with Bupivacaine.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[J02AX01, flucytosine, Levobupivacaine may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Levobupivacaine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of methemoglobinemia can be increased when Flunarizine is combined with Bupivacaine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Melitracen.]
[V03AZ01, ethanol, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The risk or severity of methemoglobinemia can be increased when Floxuridine is combined with Bupivacaine.]
[L01BC02, fluorouracil, The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Bupivacaine.]
[N06AB03, fluoxetine, The serum concentration of Bupivacaine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Flurazepam.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluspirilene.]
[L02BB01, flutamide, The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Bupivacaine.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[S02AA17, fosfomycin, The risk or severity of methemoglobinemia can be increased when Fosfomycin is combined with Bupivacaine.]
[S01AA07, framycetin, The risk or severity of methemoglobinemia can be increased when Framycetin is combined with Bupivacaine.]
[L01BC03, tegafur, The risk or severity of methemoglobinemia can be increased when Tegafur is combined with Bupivacaine.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Bupivacaine.]
[J05AE10, darunavir, The metabolism of Bupivacaine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Bupivacaine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Bupivacaine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Gallamine.]
[S01AD09, ganciclovir, Levobupivacaine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, The risk or severity of methemoglobinemia can be increased when Barbexaclone is combined with Bupivacaine.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Levobupivacaine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of methemoglobinemia can be increased when Telavancin is combined with Bupivacaine.]
[L02BX02, degarelix, The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Bupivacaine.]
[L01EA02, dasatinib, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Bupivacaine.]
[N04BC06, cabergoline, The risk or severity of methemoglobinemia can be increased when Cabergoline is combined with Bupivacaine.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Levobupivacaine.]
[N03AD03, methsuximide, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Bupivacaine.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of methemoglobinemia can be increased when Lapatinib is combined with Bupivacaine.]
[A10BB07, glipizide, Levobupivacaine may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Glutethimide.]
[C05AE01, nitroglycerin, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Nitroglycerin.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Doxazosin.]
[L01EX02, sorafenib, The risk or severity of methemoglobinemia can be increased when Sorafenib is combined with Bupivacaine.]
[C07AB09, esmolol, The serum concentration of Bupivacaine can be increased when it is combined with Esmolol.]
[M01CB04, aurothioglucose, Levobupivacaine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Levobupivacaine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[R02AB30, gramicidin, The risk or severity of methemoglobinemia can be increased when Gramicidin D is combined with Bupivacaine.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Fosinopril.]
[S01EX01, guanethidine, Bupivacaine may increase the hypotensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Levobupivacaine.]
[P01BX01, halofantrine, The risk or severity of methemoglobinemia can be increased when Halofantrine is combined with Bupivacaine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Bupivacaine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Halothane.]
[N05AH04, quetiapine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N06BX13, idebenone, Levobupivacaine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Iprazochrome.]
[L01CE02, irinotecan, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Bupivacaine.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Allobarbital.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Losartan.]
[G03DC01, allylestrenol, Levobupivacaine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of methemoglobinemia can be increased when Altretamine is combined with Bupivacaine.]
[N05CA16, hexobarbital, The risk or severity of methemoglobinemia can be increased when Hexobarbital is combined with Bupivacaine.]
[J05AG01, nevirapine, The metabolism of Bupivacaine can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Bupivacaine can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Perindopril.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydroflumethiazide.]
[B05XA17, potassium acetate, Levobupivacaine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[G04BD06, propiverine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Bupivacaine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Prothipendyl.]
[B05AA07, hetastarch, Levobupivacaine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of methemoglobinemia can be increased when Hydroxyurea is combined with Bupivacaine.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.]
[J04AB04, rifabutin, The risk or severity of methemoglobinemia can be increased when Rifabutin is combined with Bupivacaine.]
[C02AC06, rilmenidine, Bupivacaine may increase the hypotensive activities of Rilmenidine.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[B05XA08, sodium acetate, Levobupivacaine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The risk or severity of methemoglobinemia can be increased when Idarubicin is combined with Bupivacaine.]
[L01AA06, ifosfamide, The risk or severity of methemoglobinemia can be increased when Ifosfamide is combined with Bupivacaine.]
[H01AC02, somatrem, The metabolism of Levobupivacaine can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sufentanil.]
[N06AA02, imipramine, The metabolism of Bupivacaine can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Bupivacaine.]
[L01CD03, paclitaxel poliglumex, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Bupivacaine.]
[J01XA02, teicoplanin, The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Bupivacaine.]
[R01AD07, tixocortol, Levobupivacaine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of methemoglobinemia can be increased when Tizanidine is combined with Bupivacaine.]
[L01CE01, topotecan, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Bupivacaine.]
[C03BA11, indapamide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Indapamide.]
[S01BC01, indomethacin, Indomethacin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Indoramin.]
[A11HA07, inositol, Levobupivacaine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of methemoglobinemia can be increased when Interferon alfa-2a is combined with Levobupivacaine.]
[L03AB05, interferon alfa-2b, The risk or severity of methemoglobinemia can be increased when Interferon alfa-2b is combined with Levobupivacaine.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Milnacipran.]
[A03AA30, piperidolate, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Levobupivacaine may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Articaine.]
[A10BH01, sitagliptin, Levobupivacaine may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Alprazolam.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ramelteon.]
[R06AE01, buclizine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Bupivacaine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of methemoglobinemia can be increased when Anagrelide is combined with Levobupivacaine.]
[C07AA01, alprenolol, The serum concentration of Bupivacaine can be increased when it is combined with Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The metabolism of Levobupivacaine can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Bupivacaine.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Iprindole.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Bupivacaine.]
[J05AB13, penciclovir, The metabolism of Levobupivacaine can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Bupivacaine.]
[P01AX06, atovaquone, The risk or severity of methemoglobinemia can be increased when Atovaquone is combined with Bupivacaine.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Isoflurane.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Entacapone.]
[J04AC01, isoniazid, The risk or severity of methemoglobinemia can be increased when Isoniazid is combined with Bupivacaine.]
[J05AX05, inosine pranobex, Levobupivacaine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Isoxsuprine.]
[J01FA07, josamycin, The risk or severity of methemoglobinemia can be increased when Josamycin is combined with Bupivacaine.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Bupivacaine.]
[S01AA24, kanamycin, The risk or severity of methemoglobinemia can be increased when Kanamycin is combined with Bupivacaine.]
[H01AC01, somatropin, The metabolism of Levobupivacaine can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Bupivacaine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketanserin.]
[B01AC22, prasugrel, Levobupivacaine may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Bupivacaine can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Bupivacaine can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[V03AC03, deferasirox, The serum concentration of Levobupivacaine can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Bupivacaine can be increased when combined with Abatacept.]
[N04BC09, rotigotine, Bupivacaine may increase the sedative activities of Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[J01MB02, nalidixic acid, The risk or severity of methemoglobinemia can be increased when Nalidixic acid is combined with Bupivacaine.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AG01, labetalol, The serum concentration of Bupivacaine can be increased when it is combined with Labetalol.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C02AA05, deserpidine, Bupivacaine may increase the hypotensive activities of Deserpidine.]
[A06AX03, lubiprostone, Levobupivacaine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Bupivacaine.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Etacrynic acid.]
[J01CA11, amdinocillin, The risk or severity of methemoglobinemia can be increased when Amdinocillin is combined with Bupivacaine.]
[J01CA08, amdinocillin pivoxil, The risk or severity of methemoglobinemia can be increased when Pivmecillinam is combined with Bupivacaine.]
[L01DC03, mitomycin, The risk or severity of methemoglobinemia can be increased when Mitomycin is combined with Bupivacaine.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Bupivacaine is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Levobupivacaine.]
[J01FF02, lincomycin, The risk or severity of methemoglobinemia can be increased when Lincomycin is combined with Bupivacaine.]
[S01AA21, amikacin, The risk or severity of methemoglobinemia can be increased when Amikacin is combined with Bupivacaine.]
[N06BA13, armodafinil, The metabolism of Levobupivacaine can be increased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Amiloride.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Lofepramine.]
[L01AD02, lomustine, The risk or severity of methemoglobinemia can be increased when Lomustine is combined with Bupivacaine.]
[N05BA06, lorazepam, The risk or severity of methemoglobinemia can be increased when Lorazepam is combined with Levobupivacaine.]
[C10AA02, lovastatin, The metabolism of Bupivacaine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Loxapine.]
[J01AA04, lymecycline, The risk or severity of methemoglobinemia can be increased when Lymecycline is combined with Bupivacaine.]
[L01EG01, temsirolimus, The risk or severity of methemoglobinemia can be increased when Temsirolimus is combined with Bupivacaine.]
[B05XA11, magnesium chloride, Levobupivacaine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Levobupivacaine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Bupivacaine can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Bupivacaine.]
[L01EA03, nilotinib, The metabolism of Bupivacaine can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Mannitol.]
[N06AA21, maprotiline, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Mazindol.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Mecamylamine.]
[L01AA05, mechlorethamine, The risk or severity of methemoglobinemia can be increased when Mechlorethamine is combined with Bupivacaine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Meclizine.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05BA03, medazepam, The risk or severity of methemoglobinemia can be increased when Medazepam is combined with Bupivacaine.]
[P01BC02, mefloquine, The risk or severity of methemoglobinemia can be increased when Mefloquine is combined with Bupivacaine.]
[J01FG01, pristinamycin, The risk or severity of methemoglobinemia can be increased when Pristinamycin is combined with Bupivacaine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Melatonin.]
[L01AA03, melphalan, The risk or severity of methemoglobinemia can be increased when Melphalan is combined with Bupivacaine.]
[N06DX01, memantine, Levobupivacaine may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Meperidine.]
[N03AB04, mephenytoin, The risk or severity of methemoglobinemia can be increased when Mephenytoin is combined with Bupivacaine.]
[N03AA01, mephobarbital, The risk or severity of methemoglobinemia can be increased when Methylphenobarbital is combined with Bupivacaine.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Meptazinol.]
[G04BX16, tiopronin, Levobupivacaine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The risk or severity of methemoglobinemia can be increased when Aminoglutethimide is combined with Bupivacaine.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Paliperidone.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dolasetron.]
[H01CB03, lanreotide, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Bupivacaine.]
[J01AA05, methacycline, The risk or severity of methemoglobinemia can be increased when Metacycline is combined with Bupivacaine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Bupivacaine.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Metamfetamine.]
[A03AB07, methantheline, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Methaqualone.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of methemoglobinemia can be increased when Metharbital is combined with Bupivacaine.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Methazolamide.]
[L01XD04, aminolevulinic acid, The risk or severity of methemoglobinemia can be increased when Aminolevulinic acid is combined with Bupivacaine.]
[J01XX05, methenamine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Bupivacaine.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Bupivacaine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of methemoglobinemia can be increased when Pemetrexed is combined with Bupivacaine.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of methemoglobinemia can be increased when Methohexital is combined with Bupivacaine.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Ziconotide.]
[L04AX03, methotrexate, The risk or severity of methemoglobinemia can be increased when Methotrexate is combined with Bupivacaine.]
[N05AA02, methotrimeprazine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Levobupivacaine can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bupivacaine.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Bupivacaine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Levobupivacaine.]
[H02AB04, methylprednisolone, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Bupivacaine.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Bupivacaine.]
[G03EK01, methyltestosterone, The risk or severity of methemoglobinemia can be increased when Methyltestosterone is combined with Bupivacaine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Bupivacaine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Bupivacaine.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Metolazone.]
[C07AB02, metoprolol, The serum concentration of Bupivacaine can be increased when it is combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of methemoglobinemia can be increased when Metronidazole is combined with Bupivacaine.]
[V04CD01, metyrapone, Levobupivacaine may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Bupivacaine.]
[J01CA10, mezlocillin, The risk or severity of methemoglobinemia can be increased when Mezlocillin is combined with Bupivacaine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Bupivacaine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Bupivacaine.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Midazolam.]
[G03XB01, mifepristone, The metabolism of Bupivacaine can be decreased when combined with Mifepristone.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Bupivacaine.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Minoxidil.]
[J01FA11, miocamycin, The risk or severity of methemoglobinemia can be increased when Miocamycin is combined with Bupivacaine.]
[L01DC02, plicamycin, The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Bupivacaine.]
[L01AX01, mitobronitol, The risk or severity of methemoglobinemia can be increased when Mitobronitol is combined with Bupivacaine.]
[L01XX23, mitotane, The risk or severity of methemoglobinemia can be increased when Mitotane is combined with Bupivacaine.]
[L01DB07, mitoxantrone, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Bupivacaine.]
[N06BA12, lisdexamfetamine, The metabolism of Bupivacaine can be decreased when combined with Lisdexamfetamine.]
[L03AA03, molgramostim, The risk or severity of methemoglobinemia can be increased when Molgramostim is combined with Bupivacaine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Molindone.]
[L03AC01, aldesleukin, The risk or severity of methemoglobinemia can be increased when Aldesleukin is combined with Bupivacaine.]
[C01BD01, amiodarone, The metabolism of Bupivacaine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Bupivacaine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Bupivacaine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Palonosetron.]
[J01DD06, moxalactam, The risk or severity of methemoglobinemia can be increased when Latamoxef is combined with Bupivacaine.]
[L04AB05, certolizumab pegol, The metabolism of Bupivacaine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Levobupivacaine.]
[G04BA01, ammonium chloride, Levobupivacaine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Bupivacaine.]
[L01EX03, pazopanib, The risk or severity of methemoglobinemia can be increased when Pazopanib is combined with Bupivacaine.]
[L04AA06, mycophenolic acid, The risk or severity of methemoglobinemia can be increased when Mycophenolic acid is combined with Bupivacaine.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of methemoglobinemia can be increased when Amobarbital is combined with Bupivacaine.]
[P01BA06, amodiaquine, The risk or severity of methemoglobinemia can be increased when Amodiaquine is combined with Bupivacaine.]
[R03BB01, ipratropium bromide, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Bupivacaine.]
[N03AB05, fosphenytoin, The risk or severity of methemoglobinemia can be increased when Fosphenytoin is combined with Bupivacaine.]
[L03AB08, interferon beta-1b, The metabolism of Levobupivacaine can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The serum concentration of Bupivacaine can be increased when it is combined with Nadolol.]
[J01CA04, amoxicillin, The risk or severity of methemoglobinemia can be increased when Amoxicillin is combined with Bupivacaine.]
[N04BC04, ropinirole, Bupivacaine may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The risk or severity of methemoglobinemia can be increased when Nafcillin is combined with Bupivacaine.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Bupivacaine can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Levobupivacaine can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[M02AA12, naproxen, The metabolism of Levobupivacaine can be decreased when combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Bupivacaine is combined with Duloxetine.]
[S01AA10, natamycin, The risk or severity of methemoglobinemia can be increased when Natamycin is combined with Bupivacaine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tolcapone.]
[L01CD02, docetaxel, The risk or severity of methemoglobinemia can be increased when Docetaxel is combined with Bupivacaine.]
[L02BG04, letrozole, The risk or severity of methemoglobinemia can be increased when Letrozole is combined with Bupivacaine.]
[S03AA01, neomycin, The risk or severity of methemoglobinemia can be increased when Neomycin is combined with Bupivacaine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Levosimendan.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Bupivacaine.]
[S01AA19, ampicillin, The risk or severity of methemoglobinemia can be increased when Ampicillin is combined with Bupivacaine.]
[L03AX16, plerixafor, Levobupivacaine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, The risk or severity of methemoglobinemia can be increased when Netilmicin is combined with Bupivacaine.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C01CE01, inamrinone, Levobupivacaine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of methemoglobinemia can be increased when Amsacrine is combined with Bupivacaine.]
[C10AD02, niacin, The metabolism of Bupivacaine can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Bupivacaine.]
[C08CA04, nicardipine, The metabolism of Bupivacaine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Bupivacaine.]
[P02DA01, niclosamide, The metabolism of Levobupivacaine can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[V03AB22, amyl nitrite, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of methemoglobinemia can be increased when Nitrazepam is combined with Bupivacaine.]
[C08CA08, nitrendipine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Nitric Oxide.]
[J01XE01, nitrofurantoin, The risk or severity of methemoglobinemia can be increased when Nitrofurantoin is combined with Bupivacaine.]
[N05CF03, zaleplon, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Bupivacaine.]
[N04BC05, pramipexole, Bupivacaine may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nomifensine.]
[S01AE02, norfloxacin, The risk or severity of methemoglobinemia can be increased when Norfloxacin is combined with Bupivacaine.]
[C02KX01, bosentan, Bupivacaine may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Bupivacaine.]
[L03AB07, interferon beta-1a, The metabolism of Levobupivacaine can be decreased when combined with Interferon beta-1a.]
[H01CB02, octreotide, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Bupivacaine.]
[S02AA16, ofloxacin, The risk or severity of methemoglobinemia can be increased when Ofloxacin is combined with Bupivacaine.]
[J01FA05, oleandomycin, The risk or severity of methemoglobinemia can be increased when Oleandomycin is combined with Bupivacaine.]
[L04AC04, rilonacept, The metabolism of Bupivacaine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Bupivacaine can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Opium.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Tamsulosin.]
[J01CF04, oxacillin, The risk or severity of methemoglobinemia can be increased when Oxacillin is combined with Bupivacaine.]
[P02BA02, oxamniquine, The metabolism of Bupivacaine can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of methemoglobinemia can be increased when Oxolinic acid is combined with Bupivacaine.]
[C07AA02, oxprenolol, The serum concentration of Bupivacaine can be increased when it is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[A03AB03, oxyphenonium, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[S01AA04, oxytetracycline, The risk or severity of methemoglobinemia can be increased when Oxytetracycline is combined with Bupivacaine.]
[J04AA01, aminosalicylic acid, The risk or severity of methemoglobinemia can be increased when Aminosalicylic acid is combined with Bupivacaine.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.]
[M03AC01, pancuronium, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, The risk or severity of methemoglobinemia can be increased when Capreomycin is combined with Bupivacaine.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Papaverine.]
[N05CC05, paraldehyde, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Bupivacaine.]
[A07AA06, paromomycin, The risk or severity of methemoglobinemia can be increased when Paromomycin is combined with Bupivacaine.]
[J01MA03, pefloxacin, The risk or severity of methemoglobinemia can be increased when Pefloxacin is combined with Bupivacaine.]
[G04BD11, fesoterodine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The serum concentration of Bupivacaine can be increased when it is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Penfluridol.]
[S01AA14, penicillin G, The risk or severity of methemoglobinemia can be increased when Benzylpenicillin is combined with Bupivacaine.]
[J01CE09, penicillin G procaine, The risk or severity of methemoglobinemia can be increased when Procaine benzylpenicillin is combined with Bupivacaine.]
[J01CE02, penicillin V, The risk or severity of methemoglobinemia can be increased when Phenoxymethylpenicillin is combined with Bupivacaine.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of methemoglobinemia can be increased when Pentobarbital is combined with Bupivacaine.]
[L01XX08, pentostatin, The risk or severity of methemoglobinemia can be increased when Pentostatin is combined with Bupivacaine.]
[C04AD03, pentoxifylline, The metabolism of Levobupivacaine can be decreased when combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Pergolide.]
[C08EX02, perhexiline, The metabolism of Bupivacaine can be decreased when combined with Perhexiline.]
[L01FX01, edrecolomab, The risk or severity of methemoglobinemia can be increased when Edrecolomab is combined with Bupivacaine.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Bupivacaine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenazocine.]
[G04BX06, phenazopyridine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Phenazopyridine.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Bupivacaine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Bupivacaine.]
[N03AA02, phenobarbital, The risk or severity of methemoglobinemia can be increased when Phenobarbital is combined with Bupivacaine.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Phenoxybenzamine.]
[V03AB36, phentolamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Phentolamine.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[S01GA05, phenylephrine, The metabolism of Levobupivacaine can be increased when combined with Phenylephrine.]
[N03AB02, phenytoin, The risk or severity of methemoglobinemia can be increased when Phenytoin is combined with Levobupivacaine.]
[L01XF02, alitretinoin, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Bupivacaine.]
[L04AB06, golimumab, The metabolism of Bupivacaine can be increased when combined with Golimumab.]
[S01AE08, besifloxacin, The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Bupivacaine.]
[S01AE05, levofloxacin, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Bupivacaine.]
[L02BB03, bicalutamide, The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Bupivacaine.]
[B02BA01, vitamin K1, Levobupivacaine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C08CX01, mibefradil, The metabolism of Bupivacaine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Bupivacaine.]
[C07AA03, pindolol, The serum concentration of Bupivacaine can be increased when it is combined with Pindolol.]
[J01CA12, piperacillin, The risk or severity of methemoglobinemia can be increased when Piperacillin is combined with Bupivacaine.]
[J05AE01, saquinavir, The metabolism of Bupivacaine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Bupivacaine.]
[L01AX02, pipobroman, The risk or severity of methemoglobinemia can be increased when Pipobroman is combined with Bupivacaine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Pipotiazine.]
[N06BX03, piracetam, Levobupivacaine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Eprosartan.]
[A02BX03, pirenzepine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[J01DD16, cefditoren, The risk or severity of methemoglobinemia can be increased when Cefditoren is combined with Bupivacaine.]
[J01MA11, grepafloxacin, The risk or severity of methemoglobinemia can be increased when Grepafloxacin is combined with Bupivacaine.]
[J01CA02, pivampicillin, The risk or severity of methemoglobinemia can be increased when Pivampicillin is combined with Bupivacaine.]
[N02CX01, pizotyline, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Bupivacaine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Proxibarbal.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L02BG03, anastrozole, The risk or severity of methemoglobinemia can be increased when Anastrozole is combined with Bupivacaine.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Bupivacaine can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, The risk or severity of methemoglobinemia can be increased when Polymyxin B is combined with Bupivacaine.]
[C03AA05, polythiazide, Bupivacaine may increase the hypotensive activities of Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Bupivacaine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Levobupivacaine may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AB01, practolol, The serum concentration of Bupivacaine can be increased when it is combined with Practolol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Levobupivacaine.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Prazosin.]
[L01AA08, prednimustine, The risk or severity of methemoglobinemia can be increased when Prednimustine is combined with Bupivacaine.]
[S03BA02, prednisolone, The risk or severity of methemoglobinemia can be increased when Prednisolone is combined with Bupivacaine.]
[H02AB07, prednisone, The risk or severity of methemoglobinemia can be increased when Prednisone is combined with Bupivacaine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Bupivacaine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The risk or severity of methemoglobinemia can be increased when Primidone is combined with Bupivacaine.]
[M04AB01, probenecid, Levobupivacaine may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Bupivacaine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Bupivacaine.]
[C10AB05, fenofibrate, Levobupivacaine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Prochlorperazine.]
[N04AA04, procyclidine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Bupivacaine.]
[N05AA03, promazine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The serum concentration of Bupivacaine can be increased when it is combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Propanidid.]
[A03AB05, propantheline, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Periciazine.]
[N05CM06, propiomazine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Bupivacaine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Bupivacaine can be increased when it is combined with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Rizatriptan.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Epoprostenol.]
[J04AD01, prothionamide, The risk or severity of methemoglobinemia can be increased when Protionamide is combined with Bupivacaine.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Protriptyline.]
[N05AX12, aripiprazole, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Bupivacaine is combined with Dalfampridine.]
[A03AB15, diphemanil, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Talbutal.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Pyrantel.]
[J04AK01, pyrazinamide, The risk or severity of methemoglobinemia can be increased when Pyrazinamide is combined with Bupivacaine.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Mepyramine.]
[P01BD01, pyrimethamine, The risk or severity of methemoglobinemia can be increased when Pyrimethamine is combined with Bupivacaine.]
[P01AX05, quinacrine, The risk or severity of methemoglobinemia can be increased when Quinacrine is combined with Bupivacaine.]
[C01BA01, quinidine, The risk or severity of methemoglobinemia can be increased when Quinidine is combined with Bupivacaine.]
[P01BC01, quinine, The metabolism of Bupivacaine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Bupivacaine can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Bupivacaine may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Bupivacaine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[J04AB02, rifampin, The risk or severity of methemoglobinemia can be increased when Rifampicin is combined with Bupivacaine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxitriptan.]
[J01AA09, rolitetracycline, The risk or severity of methemoglobinemia can be increased when Rolitetracycline is combined with Bupivacaine.]
[J01FA06, roxithromycin, The risk or severity of methemoglobinemia can be increased when Roxithromycin is combined with Bupivacaine.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[A07EC01, sulfasalazine, The risk or severity of methemoglobinemia can be increased when Sulfasalazine is combined with Bupivacaine.]
[S01BC08, salicylic acid, Salicylic acid may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[S01FA02, scopolamine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of methemoglobinemia can be increased when Secobarbital is combined with Bupivacaine.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Bupivacaine.]
[L01FA03, obinutuzumab, The risk or severity of methemoglobinemia can be increased when Obinutuzumab is combined with Bupivacaine.]
[D06BA01, silver sulfadiazine, The risk or severity of methemoglobinemia can be increased when Silver sulfadiazine is combined with Bupivacaine.]
[J01GB08, sisomicin, The risk or severity of methemoglobinemia can be increased when Sisomicin is combined with Bupivacaine.]
[A12CD01, sodium fluoride, Levobupivacaine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Levobupivacaine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The serum concentration of Bupivacaine can be increased when it is combined with Sotalol.]
[L01CD04, cabazitaxel, The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Bupivacaine.]
[J01FA02, spiramycin, The risk or severity of methemoglobinemia can be increased when Spiramycin is combined with Bupivacaine.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Spironolactone.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of methemoglobinemia can be increased when Trastuzumab emtansine is combined with Bupivacaine.]
[V09AB03, ioflupane I-123, Levobupivacaine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09IA09, technetium Tc 99m tilmanocept, Bupivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.]
[V09AA01, technetium Tc 99m exametazime, Levobupivacaine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Levobupivacaine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[N03AG01, valproic acid, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Bupivacaine.]
[S02DA03, antipyrine, The risk or severity of adverse effects can be increased when Meloxicam is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Streptokinase.]
[J01GA01, streptomycin, The risk or severity of methemoglobinemia can be increased when Streptomycin is combined with Meloxicam.]
[L01AD04, streptozocin, The risk or severity of methemoglobinemia can be increased when Streptozocin is combined with Meloxicam.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Meloxicam.]
[A02BX02, sucralfate, Meloxicam may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Meloxicam may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01CA16, sulbenicillin, The risk or severity of methemoglobinemia can be increased when Sulbenicillin is combined with Meloxicam.]
[S01AB04, sulfacetamide, The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Meloxicam.]
[J01EC02, sulfadiazine, The risk or severity of methemoglobinemia can be increased when Sulfadiazine is combined with Meloxicam.]
[J01ED07, sulfamerazine, The risk or severity of methemoglobinemia can be increased when Sulfamerazine is combined with Meloxicam.]
[S01AB01, sulfamethizole, The metabolism of Meloxicam can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Meloxicam.]
[J01ED05, sulfamethoxypyridazine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxypyridazine is combined with Meloxicam.]
[J01EC03, sulfamoxole, The metabolism of Meloxicam can be decreased when combined with Sulfamoxole.]
[J01EB06, sulfanilamide, The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Meloxicam.]
[J01EB04, sulfapyridine, The metabolism of Meloxicam can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Meloxicam is combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of methemoglobinemia can be increased when Sulfisoxazole is combined with Meloxicam.]
[M01AB02, sulindac, The risk or severity of adverse effects can be increased when Sulindac is combined with Meloxicam.]
[N03AX03, sulthiame, The risk or severity of methemoglobinemia can be increased when Sulthiame is combined with Meloxicam.]
[M01AE07, suprofen, The risk or severity of adverse effects can be increased when Meloxicam is combined with Suprofen.]
[A10BB04, glibornuride, The protein binding of Glibornuride can be decreased when combined with Meloxicam.]
[M01AX04, apazone, The risk or severity of adverse effects can be increased when Meloxicam is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of methemoglobinemia can be increased when Mercaptopurine is combined with Meloxicam.]
[J01CA15, talampicillin, The risk or severity of methemoglobinemia can be increased when Talampicillin is combined with Meloxicam.]
[L02BA01, tamoxifen, The risk or severity of methemoglobinemia can be increased when Tamoxifen is combined with Meloxicam.]
[N05CD07, temazepam, Meloxicam may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[L01CB02, teniposide, The risk or severity of methemoglobinemia can be increased when Teniposide is combined with Meloxicam.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Meloxicam is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Dabigatran etexilate.]
[G03BA03, testosterone, Meloxicam may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Tetracaine.]
[S03AA02, tetracycline, The risk or severity of methemoglobinemia can be increased when Tetracycline is combined with Meloxicam.]
[J01DI02, ceftaroline fosamil, The risk or severity of methemoglobinemia can be increased when Ceftaroline fosamil is combined with Meloxicam.]
[N05AE05, lurasidone, The risk or severity of hypertension can be increased when Meloxicam is combined with Lurasidone.]
[A04AD10, dronabinol, The metabolism of Meloxicam can be decreased when combined with Dronabinol.]
[L04AX02, thalidomide, The risk or severity of methemoglobinemia can be increased when Thalidomide is combined with Meloxicam.]
[R03DA07, theobromine, The therapeutic efficacy of Theobromine can be decreased when used in combination with Meloxicam.]
[P02CA02, thiabendazole, Meloxicam may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of methemoglobinemia can be increased when Eribulin is combined with Meloxicam.]
[J01BA02, thiamphenicol, The risk or severity of methemoglobinemia can be increased when Thiamphenicol is combined with Meloxicam.]
[R06AD03, thiethylperazine, Meloxicam may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[L01AC01, thiotepa, The risk or severity of methemoglobinemia can be increased when Thiotepa is combined with Meloxicam.]
[L01BB03, thioguanine, The risk or severity of methemoglobinemia can be increased when Tioguanine is combined with Meloxicam.]
[N05CA19, thiopental, The risk or severity of methemoglobinemia can be increased when Thiopental is combined with Meloxicam.]
[N05AB08, thioproperazine, The risk or severity of hypertension can be increased when Meloxicam is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of hypertension can be increased when Thioridazine is combined with Meloxicam.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Meloxicam is combined with Moxisylyte.]
[N05AL03, tiapride, Meloxicam may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[J01CA13, ticarcillin, The risk or severity of methemoglobinemia can be increased when Ticarcillin is combined with Meloxicam.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Meloxicam is combined with Ticlopidine.]
[S01ED01, timolol, Meloxicam may decrease the antihypertensive activities of Timolol.]
[P01AB02, tinidazole, The risk or severity of methemoglobinemia can be increased when Tinidazole is combined with Meloxicam.]
[S01AA12, tobramycin, The risk or severity of methemoglobinemia can be increased when Tobramycin is combined with Meloxicam.]
[A10BB05, tolazamide, The protein binding of Tolazamide can be decreased when combined with Meloxicam.]
[M02AX02, tolazoline, The therapeutic efficacy of Tolazoline can be decreased when used in combination with Meloxicam.]
[V04CA01, tolbutamide, The protein binding of Tolbutamide can be decreased when combined with Meloxicam.]
[M02AA21, tolmetin, The risk or severity of adverse effects can be increased when Tolmetin is combined with Meloxicam.]
[N02AX02, tramadol, Meloxicam may decrease the excretion rate of Tramadol which could result in a higher serum level.]
[N06AF04, tranylcypromine, The metabolism of Meloxicam can be decreased when combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Meloxicam is combined with Trapidil.]
[N06AX05, trazodone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Meloxicam.]
[L01XF01, tretinoin, The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Meloxicam.]
[S01BA05, triamcinolone, The risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Meloxicam.]
[C03DB02, triamterene, The therapeutic efficacy of Triamterene can be decreased when used in combination with Meloxicam.]
[N05CD05, triazolam, Meloxicam may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meloxicam.]
[A16AX12, trientine, Meloxicam may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of hypertension can be increased when Meloxicam is combined with Trifluoperazine.]
[S01AD02, trifluridine, The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Meloxicam.]
[D07AC02, fluclorolone, The risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Meloxicam.]
[R03BA07, mometasone, The risk or severity of gastrointestinal irritation can be increased when Mometasone is combined with Meloxicam.]
[A03AA05, trimebutine, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Trimebutine.]
[N03AC02, trimethadione, The risk or severity of methemoglobinemia can be increased when Trimethadione is combined with Meloxicam.]
[C02BA01, trimethaphan, The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Meloxicam.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Meloxicam.]
[N06AA06, trimipramine, The risk or severity of gastrointestinal bleeding can be increased when Trimipramine is combined with Meloxicam.]
[J01FA08, troleandomycin, The metabolism of Meloxicam can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of hypertension can be increased when Meloxicam is combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Meloxicam.]
[R03DX07, roflumilast, Meloxicam may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Meloxicam.]
[S01AA05, tyrothricin, The risk or severity of methemoglobinemia can be increased when Tyrothricin is combined with Meloxicam.]
[L01EX04, vandetanib, The risk or severity of methemoglobinemia can be increased when Vandetanib is combined with Meloxicam.]
[L01AD08, uracil mustard, The risk or severity of methemoglobinemia can be increased when Uracil mustard is combined with Meloxicam.]
[R02AA14, oxyquinoline, Meloxicam may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The risk or severity of methemoglobinemia can be increased when Abiraterone is combined with Meloxicam.]
[A10BH05, linagliptin, The metabolism of Meloxicam can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Meloxicam can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Meloxicam can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Meloxicam can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Urokinase.]
[A07AA12, fidaxomicin, The risk or severity of methemoglobinemia can be increased when Fidaxomicin is combined with Meloxicam.]
[S01AA28, vancomycin, Meloxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of methemoglobinemia can be increased when Ezogabine is combined with Meloxicam.]
[B01AF01, rivaroxaban, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Meloxicam can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Meloxicam can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The risk or severity of methemoglobinemia can be increased when Vinblastine is combined with Meloxicam.]
[C04AX07, vincamine, The risk or severity of methemoglobinemia can be increased when Vincamine is combined with Meloxicam.]
[L01CA02, vincristine, The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Meloxicam.]
[L01CA03, vindesine, The risk or severity of methemoglobinemia can be increased when Vindesine is combined with Meloxicam.]
[B03BA01, vitamin B12, Meloxicam may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Meloxicam is combined with Warfarin.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Meloxicam is combined with Xenon.]
[C03BA10, xipamide, The therapeutic efficacy of Xipamide can be decreased when used in combination with Meloxicam.]
[J05AF01, zidovudine, The risk or severity of bleeding can be increased when Zidovudine is combined with Meloxicam.]
[N05AF05, zuclopenthixol, The risk or severity of hypertension can be increased when Meloxicam is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Meloxicam can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of methemoglobinemia can be increased when Levetiracetam is combined with Meloxicam.]
[L01EC01, vemurafenib, The risk or severity of methemoglobinemia can be increased when Vemurafenib is combined with Meloxicam.]
[M05BA03, pamidronic acid, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Meloxicam.]
[L01FX05, brentuximab vedotin, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Meloxicam.]
[M05BA05, tiludronic acid, The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Tiludronic acid.]
[B06AC02, icatibant, Meloxicam may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The risk or severity of methemoglobinemia can be increased when Crizotinib is combined with Meloxicam.]
[B01AE01, desirudin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Meloxicam can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Meloxicam may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[L01XD05, temoporfin, The risk or severity of methemoglobinemia can be increased when Temoporfin is combined with Meloxicam.]
[M05BA06, ibandronic acid, The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of methemoglobinemia can be increased when Trovafloxacin is combined with Meloxicam.]
[L01XX02, asparaginase, The risk or severity of methemoglobinemia can be increased when Asparaginase Escherichia coli is combined with Meloxicam.]
[N05AE04, ziprasidone, The metabolism of Meloxicam can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Drospirenone.]
[V03AC02, deferiprone, Meloxicam may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of methemoglobinemia can be increased when Alemtuzumab is combined with Meloxicam.]
[N02BA01, aspirin, The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Meloxicam.]
[G04BD07, tolterodine, Meloxicam may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, The risk or severity of methemoglobinemia can be increased when Doripenem is combined with Meloxicam.]
[C07AB03, atenolol, Meloxicam may decrease the antihypertensive activities of Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of methemoglobinemia can be increased when Peginterferon alfa-2a is combined with Meloxicam.]
[L01FA01, rituximab, The risk or severity of methemoglobinemia can be increased when Rituximab is combined with Meloxicam.]
[J02AC03, voriconazole, The serum concentration of Meloxicam can be increased when it is combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Atropine is combined with Meloxicam.]
[M01CB03, auranofin, Meloxicam may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The risk or severity of methemoglobinemia can be increased when Vismodegib is combined with Meloxicam.]
[L01EK01, axitinib, The risk or severity of methemoglobinemia can be increased when Axitinib is combined with Meloxicam.]
[S01EE05, tafluprost, The therapeutic efficacy of Tafluprost can be decreased when used in combination with Meloxicam.]
[H02AB11, prednylidene, The risk or severity of gastrointestinal irritation can be increased when Prednylidene is combined with Meloxicam.]
[B03XA04, peginesatide, Meloxicam may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, The risk or severity of methemoglobinemia can be increased when Azacitidine is combined with Meloxicam.]
[L04AX01, azathioprine, Meloxicam may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, The risk or severity of methemoglobinemia can be increased when Gemcitabine is combined with Meloxicam.]
[J01CA09, azlocillin, The risk or severity of methemoglobinemia can be increased when Azlocillin is combined with Meloxicam.]
[J01DF01, aztreonam, The risk or severity of methemoglobinemia can be increased when Aztreonam is combined with Meloxicam.]
[R02AB04, bacitracin, The risk or severity of methemoglobinemia can be increased when Bacitracin is combined with Meloxicam.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Meloxicam.]
[M03BX01, baclofen, Meloxicam may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Meloxicam.]
[L01FD02, pertuzumab, The risk or severity of methemoglobinemia can be increased when Pertuzumab is combined with Meloxicam.]
[A08AA11, lorcaserin, Meloxicam may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Meloxicam is combined with Mirabegron.]
[L01XG02, carfilzomib, The risk or severity of methemoglobinemia can be increased when Carfilzomib is combined with Meloxicam.]
[V03AX03, cobicistat, The metabolism of Meloxicam can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Meloxicam can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Meloxicam can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Meloxicam.]
[B01AX01, defibrotide, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Defibrotide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Meloxicam is combined with Octopamine.]
[H02AA01, aldosterone, The risk or severity of gastrointestinal irritation can be increased when Aldosterone is combined with Meloxicam.]
[L01EX05, regorafenib, The risk or severity of methemoglobinemia can be increased when Regorafenib is combined with Meloxicam.]
[L01XL02, talimogene laherparepvec, The risk or severity of methemoglobinemia can be increased when Talimogene laherparepvec is combined with Meloxicam.]
[N05CA04, barbital, The risk or severity of methemoglobinemia can be increased when Barbital is combined with Meloxicam.]
[D02BA02, octinoxate, Meloxicam may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Meloxicam can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Meloxicam.]
[N04BD02, rasagiline, The risk or severity of hypertension can be increased when Meloxicam is combined with Rasagiline.]
[C08CA13, lercanidipine, The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Meloxicam.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Meloxicam.]
[N03AX22, perampanel, The risk or severity of methemoglobinemia can be increased when Perampanel is combined with Meloxicam.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Zolmitriptan is combined with Meloxicam.]
[V09IX04, fluorodeoxyglucose F18, Meloxicam may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Meloxicam is combined with Diethyl ether.]
[L01EX07, cabozantinib, The risk or severity of methemoglobinemia can be increased when Cabozantinib is combined with Meloxicam.]
[G04BE03, sildenafil, The metabolism of Meloxicam can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Meloxicam may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Meloxicam.]
[B01AF02, apixaban, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Apixaban.]
[A16AX08, teduglutide, Meloxicam may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of methemoglobinemia can be increased when Bedaquiline is combined with Meloxicam.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Bencyclane.]
[A10BH04, alogliptin, Meloxicam may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Meloxicam may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meloxicam.]
[L04AX06, pomalidomide, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Meloxicam.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Meloxicam.]
[N02BA10, benorilate, The risk or severity of adverse effects can be increased when Meloxicam is combined with Benorilate.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Meloxicam.]
[J01MA15, gemifloxacin, The risk or severity of methemoglobinemia can be increased when Gemifloxacin is combined with Meloxicam.]
[M04AB03, benzbromarone, The metabolism of Meloxicam can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Meloxicam.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Benzocaine.]
[L03AA12, ancestim, Meloxicam may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of adverse effects can be increased when Celecoxib is combined with Meloxicam.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Meloxicam is combined with Naratriptan.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The risk or severity of methemoglobinemia can be increased when Everolimus is combined with Meloxicam.]
[N04AC01, benztropine, Meloxicam may decrease the excretion rate of Benzatropine which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Meloxicam can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of adverse effects can be increased when Meloxicam is combined with Benzydamine.]
[L01EE01, trametinib, The risk or severity of methemoglobinemia can be increased when Trametinib is combined with Meloxicam.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Meloxicam may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The risk or severity of methemoglobinemia can be increased when Afatinib is combined with Meloxicam.]
[N06AX28, levomilnacipran, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Meloxicam.]
[C08EA02, bepridil, The therapeutic efficacy of Bepridil can be decreased when used in combination with Meloxicam.]
[C02KX05, riociguat, The therapeutic efficacy of Riociguat can be decreased when used in combination with Meloxicam.]
[A10BJ03, lixisenatide, Meloxicam may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, The therapeutic efficacy of Macitentan can be decreased when used in combination with Meloxicam.]
[L01EL01, ibrutinib, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Meloxicam.]
[N06AX26, vortioxetine, The risk or severity of hypertension can be increased when Meloxicam is combined with Vortioxetine.]
[G03AC08, etonogestrel, Meloxicam may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Meloxicam.]
[J05AP05, simeprevir, The metabolism of Meloxicam can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Meloxicam may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Meloxicam.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Meloxicam.]
[C01CA27, droxidopa, The risk or severity of hypertension can be increased when Meloxicam is combined with Droxidopa.]
[C07AB04, acebutolol, Meloxicam may decrease the antihypertensive activities of Acebutolol.]
[N05CH03, tasimelteon, Meloxicam may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[A16AA07, metreleptin, The metabolism of Meloxicam can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Meloxicam can be increased when combined with Apremilast.]
[P01CX04, miltefosine, The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Meloxicam.]
[L02BG02, formestane, The risk or severity of methemoglobinemia can be increased when Formestane is combined with Meloxicam.]
[S03BA03, betamethasone, The risk or severity of gastrointestinal irritation can be increased when Betamethasone is combined with Meloxicam.]
[S01ED02, betaxolol, Meloxicam may decrease the antihypertensive activities of Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Argatroban.]
[V03AB34, fomepizole, Meloxicam may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Meloxicam.]
[L04AC11, siltuximab, The metabolism of Meloxicam can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Meloxicam.]
[L01FG02, ramucirumab, The risk or severity of methemoglobinemia can be increased when Ramucirumab is combined with Meloxicam.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Vorapaxar.]
[J01XA04, dalbavancin, The risk or severity of methemoglobinemia can be increased when Dalbavancin is combined with Meloxicam.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Meloxicam is combined with Acenocoumarol.]
[J01XX11, tedizolid, The risk or severity of methemoglobinemia can be increased when Tedizolid is combined with Meloxicam.]
[L01XH04, belinostat, The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Meloxicam.]
[L01EM01, idelalisib, The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Meloxicam.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Meloxicam may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[S01EE02, unoprostone, The therapeutic efficacy of Unoprostone can be decreased when used in combination with Meloxicam.]
[V03AE01, polystyrene sulfonate, The risk or severity of adverse effects can be increased when Meloxicam is combined with Tolevamer.]
[V08AA04, iothalamic acid, Meloxicam may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[L01FF02, pembrolizumab, The risk or severity of methemoglobinemia can be increased when Pembrolizumab is combined with Meloxicam.]
[J01XA05, oritavancin, The risk or severity of methemoglobinemia can be increased when Oritavancin is combined with Meloxicam.]
[S01AA15, dihydrostreptomycin, The risk or severity of methemoglobinemia can be increased when Dihydrostreptomycin is combined with Meloxicam.]
[N05AA04, acepromazine, The risk or severity of hypertension can be increased when Meloxicam is combined with Acepromazine.]
[L01BC08, decitabine, The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Meloxicam.]
[L04AX05, pirfenidone, The risk or severity of methemoglobinemia can be increased when Pirfenidone is combined with Meloxicam.]
[L01EX09, nintedanib, The risk or severity of methemoglobinemia can be increased when Nintedanib is combined with Meloxicam.]
[S03AA06, gentamicin, The risk or severity of methemoglobinemia can be increased when Gentamicin is combined with Meloxicam.]
[L01FX07, blinatumomab, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Meloxicam.]
[L01XK01, olaparib, The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Meloxicam.]
[L01FF01, nivolumab, The risk or severity of methemoglobinemia can be increased when Nivolumab is combined with Meloxicam.]
[B01AA01, dicumarol, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Edoxaban.]
[N06AX11, mirtazapine, The risk or severity of hypertension can be increased when Mirtazapine is combined with Meloxicam.]
[L04AC10, secukinumab, The metabolism of Meloxicam can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of methemoglobinemia can be increased when Palbociclib is combined with Meloxicam.]
[L01EX08, lenvatinib, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Meloxicam.]
[L01XH03, panobinostat, The risk or severity of methemoglobinemia can be increased when Panobinostat is combined with Meloxicam.]
[N02BE01, acetaminophen, The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Meloxicam.]
[L01DC01, bleomycin, The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Meloxicam.]
[B01AA11, tioclomarol, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Meloxicam.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Meloxicam.]
[B01AC25, cangrelor, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Cangrelor.]
[N05AX16, brexpiprazole, The risk or severity of hypertension can be increased when Meloxicam is combined with Brexpiprazole.]
[L01XJ02, sonidegib, The risk or severity of methemoglobinemia can be increased when Sonidegib is combined with Meloxicam.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Meloxicam is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Meloxicam is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of adverse effects can be increased when Meloxicam is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of adverse effects can be increased when Meloxicam is combined with Acemetacin.]
[S01EC01, acetazolamide, The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Meloxicam.]
[S02AA10, acetic acid, The risk or severity of methemoglobinemia can be increased when Acetic acid is combined with Meloxicam.]
[A02BC03, lansoprazole, The metabolism of Meloxicam can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Meloxicam may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of methemoglobinemia can be increased when Trabectedin is combined with Meloxicam.]
[J02AC05, isavuconazole, The metabolism of Meloxicam can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The risk or severity of methemoglobinemia can be increased when Osimertinib is combined with Meloxicam.]
[J05AF13, tenofovir alafenamide, Meloxicam may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01FC01, daratumumab, The risk or severity of methemoglobinemia can be increased when Daratumumab is combined with Meloxicam.]
[L01EE02, cobimetinib, The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Meloxicam.]
[L01XG03, ixazomib, The risk or severity of methemoglobinemia can be increased when Ixazomib is combined with Meloxicam.]
[L01FE03, necitumumab, The risk or severity of methemoglobinemia can be increased when Necitumumab is combined with Meloxicam.]
[L01FX08, elotuzumab, The risk or severity of methemoglobinemia can be increased when Elotuzumab is combined with Meloxicam.]
[L01ED03, alectinib, The risk or severity of methemoglobinemia can be increased when Alectinib is combined with Meloxicam.]
[B01AC27, selexipag, The therapeutic efficacy of Selexipag can be decreased when used in combination with Meloxicam.]
[A10BB31, acetohexamide, The protein binding of Acetohexamide can be decreased when combined with Meloxicam.]
[M04AB05, lesinurad, Meloxicam may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[L01XA04, satraplatin, The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Meloxicam.]
[M01AE16, alminoprofen, The risk or severity of adverse effects can be increased when Meloxicam is combined with Alminoprofen.]
[N02BA02, aloxiprin, The therapeutic efficacy of Aloxiprin can be decreased when used in combination with Meloxicam.]
[N03AX23, brivaracetam, The risk or severity of methemoglobinemia can be increased when Brivaracetam is combined with Meloxicam.]
[L01XX52, venetoclax, The risk or severity of methemoglobinemia can be increased when Venetoclax is combined with Meloxicam.]
[N05BA08, bromazepam, Meloxicam may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of hypertension can be increased when Meloxicam is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Meloxicam may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[N06AA19, amineptin, The risk or severity of gastrointestinal bleeding can be increased when Amineptine is combined with Meloxicam.]
[C08CA01, amlodipine, Meloxicam may decrease the antihypertensive activities of Amlodipine.]
[L01FF05, atezolizumab, The risk or severity of methemoglobinemia can be increased when Atezolizumab is combined with Meloxicam.]
[M02AA09, bufexamac, The risk or severity of adverse effects can be increased when Meloxicam is combined with Bufexamac.]
[C03CA02, bumetanide, The therapeutic efficacy of Bumetanide can be decreased when used in combination with Meloxicam.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Levobupivacaine.]
[C07AA19, bupranolol, Meloxicam may decrease the antihypertensive activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Meloxicam.]
[L02AE01, buserelin, The risk or severity of methemoglobinemia can be increased when Buserelin is combined with Meloxicam.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Buspirone is combined with Meloxicam.]
[L01AB01, busulfan, The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Meloxicam.]
[L01XX27, arsenic trioxide, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Meloxicam.]
[P01BE02, artemether, The risk or severity of methemoglobinemia can be increased when Artemether is combined with Meloxicam.]
[P01BE03, artesunate, The risk or severity of methemoglobinemia can be increased when Artesunate is combined with Meloxicam.]
[M02AA03, clofezone, Meloxicam may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of methemoglobinemia can be increased when Sparfloxacin is combined with Meloxicam.]
[L01FX10, olaratumab, The risk or severity of methemoglobinemia can be increased when Olaratumab is combined with Meloxicam.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Meloxicam.]
[J01CE04, azidocillin, The risk or severity of methemoglobinemia can be increased when Azidocillin is combined with Meloxicam.]
[L01XK03, rucaparib, The risk or severity of methemoglobinemia can be increased when Rucaparib is combined with Meloxicam.]
[S01AA26, azithromycin, The risk or severity of methemoglobinemia can be increased when Azithromycin is combined with Meloxicam.]
[J01CA06, bacampicillin, The risk or severity of methemoglobinemia can be increased when Bacampicillin is combined with Meloxicam.]
[L01EF02, ribociclib, The metabolism of Meloxicam can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The therapeutic efficacy of Balsalazide can be decreased when used in combination with Meloxicam.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Bambuterol.]
[L01FF04, avelumab, The risk or severity of methemoglobinemia can be increased when Avelumab is combined with Meloxicam.]
[A06AH05, naldemedine, Meloxicam may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Meloxicam may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The risk or severity of methemoglobinemia can be increased when Pregabalin is combined with Meloxicam.]
[N03AX30, beclamide, The risk or severity of methemoglobinemia can be increased when Beclamide is combined with Meloxicam.]
[C09AA07, benazepril, The therapeutic efficacy of Benazepril can be decreased when used in combination with Meloxicam.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Meloxicam may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of methemoglobinemia can be increased when Linezolid is combined with Meloxicam.]
[J05AF06, abacavir, Meloxicam may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Meloxicam can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Meloxicam may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L01XK02, niraparib, The risk or severity of methemoglobinemia can be increased when Niraparib is combined with Meloxicam.]
[L04AB02, infliximab, The metabolism of Meloxicam can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Meloxicam can be decreased when combined with Midostaurin.]
[L01FF03, durvalumab, The risk or severity of methemoglobinemia can be increased when Durvalumab is combined with Meloxicam.]
[L01ED04, brigatinib, The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Meloxicam.]
[N04BD03, safinamide, The risk or severity of hypertension can be increased when Meloxicam is combined with Safinamide.]
[P01AX10, fumagillin, The risk or severity of methemoglobinemia can be increased when Fumagillin is combined with Meloxicam.]
[J01MA23, delafloxacin, The risk or severity of methemoglobinemia can be increased when Delafloxacin is combined with Meloxicam.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Meloxicam.]
[L01BC06, capecitabine, The risk or severity of methemoglobinemia can be increased when Capecitabine is combined with Meloxicam.]
[L01XX59, enasidenib, The risk or severity of methemoglobinemia can be increased when Enasidenib is combined with Meloxicam.]
[L01EH02, neratinib, The risk or severity of methemoglobinemia can be increased when Neratinib is combined with Meloxicam.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Meloxicam.]
[L01XH01, vorinostat, The risk or severity of methemoglobinemia can be increased when Vorinostat is combined with Meloxicam.]
[L01EM02, copanlisib, The risk or severity of methemoglobinemia can be increased when Copanlisib is combined with Meloxicam.]
[L01EF03, abemaciclib, The risk or severity of methemoglobinemia can be increased when Abemaciclib is combined with Meloxicam.]
[C07AB07, bisoprolol, Meloxicam may decrease the antihypertensive activities of Bisoprolol.]
[S01EC04, brinzolamide, The therapeutic efficacy of Brinzolamide can be decreased when used in combination with Meloxicam.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Bitolterol.]
[J05AG03, efavirenz, The metabolism of Meloxicam can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, The risk or severity of methemoglobinemia can be increased when Cefprozil is combined with Meloxicam.]
[C07AA17, bopindolol, Meloxicam may decrease the antihypertensive activities of Bopindolol.]
[L01BA03, raltitrexed, The risk or severity of methemoglobinemia can be increased when Raltitrexed is combined with Meloxicam.]
[S01BC11, bromfenac, The risk or severity of adverse effects can be increased when Meloxicam is combined with Bromfenac.]
[C03DA03, canrenone, The therapeutic efficacy of Canrenone can be decreased when used in combination with Meloxicam.]
[R03BA02, budesonide, The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Meloxicam.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Meloxicam is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of adverse effects can be increased when Meloxicam is combined with Bumadizone.]
[L01XL04, tisagenlecleucel, The risk or severity of methemoglobinemia can be increased when Tisagenlecleucel is combined with Meloxicam.]
[L01XL03, axicabtagene ciloleucel, The risk or severity of methemoglobinemia can be increased when Axicabtagene ciloleucel is combined with Meloxicam.]
[S01EE06, latanoprostene bunod, The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Meloxicam.]
[N06AA15, butriptyline, The risk or severity of gastrointestinal bleeding can be increased when Butriptyline is combined with Meloxicam.]
[C01AA02, acetyldigoxins, Meloxicam may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Meloxicam.]
[R06AX18, acrivastine, Meloxicam may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The therapeutic efficacy of Captopril can be decreased when used in combination with Meloxicam.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Meloxicam.]
[L02BB05, apalutamide, The risk or severity of methemoglobinemia can be increased when Apalutamide is combined with Meloxicam.]
[N03AF01, carbamazepine, The risk or severity of methemoglobinemia can be increased when Carbamazepine is combined with Meloxicam.]
[J01CA03, carbenicillin, The risk or severity of methemoglobinemia can be increased when Carbenicillin is combined with Meloxicam.]
[C07AG02, carvedilol, Meloxicam may decrease the antihypertensive activities of Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of methemoglobinemia can be increased when Cannabidiol is combined with Meloxicam.]
[B02BX08, avatrombopag, The metabolism of Meloxicam can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, Meloxicam may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, The risk or severity of methemoglobinemia can be increased when Cefepime is combined with Meloxicam.]
[J01DD10, cefetamet, The risk or severity of methemoglobinemia can be increased when Cefetamet is combined with Meloxicam.]
[J01DD09, cefodizime, The risk or severity of methemoglobinemia can be increased when Cefodizime is combined with Meloxicam.]
[J01DC11, ceforanide, The risk or severity of methemoglobinemia can be increased when Ceforanide is combined with Meloxicam.]
[J01DD13, cefpodoxime, The risk or severity of methemoglobinemia can be increased when Cefpodoxime is combined with Meloxicam.]
[L01EC03, encorafenib, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Meloxicam.]
[L01EE03, binimetinib, The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Meloxicam.]
[J01DD14, ceftibuten, The risk or severity of methemoglobinemia can be increased when Ceftibuten is combined with Meloxicam.]
[J01GB14, plazomicin, The risk or severity of methemoglobinemia can be increased when Plazomicin is combined with Meloxicam.]
[C07AB08, celiprolol, Meloxicam may decrease the antihypertensive activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Meloxicam can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The risk or severity of methemoglobinemia can be increased when Tafenoquine is combined with Meloxicam.]
[L01FX09, mogamulizumab, The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Meloxicam.]
[A16AX14, migalastat, Meloxicam may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Meloxicam can be decreased when combined with Stiripentol.]
[J01AA13, eravacycline, The risk or severity of methemoglobinemia can be increased when Eravacycline is combined with Meloxicam.]
[L01EM04, duvelisib, The risk or severity of methemoglobinemia can be increased when Duvelisib is combined with Meloxicam.]
[L01FF06, cemiplimab, The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Meloxicam.]
[L01EB07, dacomitinib, The risk or severity of methemoglobinemia can be increased when Dacomitinib is combined with Meloxicam.]
[J01AA14, sarecycline, The risk or severity of methemoglobinemia can be increased when Sarecycline is combined with Meloxicam.]
[J01AA15, omadacycline, The risk or severity of methemoglobinemia can be increased when Omadacycline is combined with Meloxicam.]
[S01GX12, cetirizine, Meloxicam may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[A10BB06, carbutamide, The protein binding of Carbutamide can be decreased when combined with Meloxicam.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Meloxicam is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Meloxicam may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of adverse effects can be increased when Meloxicam is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Meloxicam is combined with Inotersen.]
[L01FB02, moxetumomab pasudotox, The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Meloxicam.]
[L01XK04, talazoparib, The risk or severity of methemoglobinemia can be increased when Talazoparib is combined with Meloxicam.]
[L01ED05, lorlatinib, The risk or severity of methemoglobinemia can be increased when Lorlatinib is combined with Meloxicam.]
[L04AA39, emapalumab, The metabolism of Meloxicam can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Meloxicam.]
[L01EX12, larotrectinib, The risk or severity of methemoglobinemia can be increased when Larotrectinib is combined with Meloxicam.]
[L01EX13, gilteritinib, The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Meloxicam.]
[L01XJ03, glasdegib, The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Meloxicam.]
[A06AX05, prucalopride, Meloxicam may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[L01XX67, tagraxofusp, The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Meloxicam.]
[C09AA08, cilazapril, The therapeutic efficacy of Cilazapril can be decreased when used in combination with Meloxicam.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Meloxicam is combined with Caplacizumab.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Meloxicam is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Meloxicam is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Meloxicam can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Meloxicam.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Meloxicam is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Meloxicam can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Meloxicam.]
[N06AX29, brexanolone, The risk or severity of methemoglobinemia can be increased when Brexanolone is combined with Meloxicam.]
[L01EN01, erdafitinib, The risk or severity of methemoglobinemia can be increased when Erdafitinib is combined with Meloxicam.]
[N05BA09, clobazam, The risk or severity of methemoglobinemia can be increased when Clobazam is combined with Meloxicam.]
[J01AA11, clomocycline, The risk or severity of methemoglobinemia can be increased when Clomocycline is combined with Meloxicam.]
[H02AB14, cloprednol, The risk or severity of gastrointestinal irritation can be increased when Cloprednol is combined with Meloxicam.]
[C09CA06, candesartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Meloxicam.]
[L01XX29, denileukin diftitox, The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Meloxicam.]
[L04AB01, etanercept, The metabolism of Meloxicam can be increased when combined with Etanercept.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of gastrointestinal irritation can be increased when Cortivazol is combined with Meloxicam.]
[L01EM03, alpelisib, The serum concentration of Meloxicam can be decreased when it is combined with Alpelisib.]
[L01FX14, polatuzumab vedotin, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Meloxicam.]
[J01DC04, cefaclor, The risk or severity of methemoglobinemia can be increased when Cefaclor is combined with Meloxicam.]
[J01DB05, cefadroxil, The risk or severity of methemoglobinemia can be increased when Cefadroxil is combined with Meloxicam.]
[J01DC03, cefamandole, The risk or severity of methemoglobinemia can be increased when Cefamandole is combined with Meloxicam.]
[L01XX66, selinexor, The risk or severity of methemoglobinemia can be increased when Selinexor is combined with Meloxicam.]
[J01DB07, cefatrizine, The risk or severity of methemoglobinemia can be increased when Cefatrizine is combined with Meloxicam.]
[J01DB04, cefazolin, The risk or severity of methemoglobinemia can be increased when Cefazolin is combined with Meloxicam.]
[L02BB06, darolutamide, The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Meloxicam.]
[J01CF03, methicillin, The risk or severity of methemoglobinemia can be increased when Meticillin is combined with Meloxicam.]
[J01DC09, cefmetazole, The risk or severity of methemoglobinemia can be increased when Cefmetazole is combined with Meloxicam.]
[J01DC06, cefonicid, The risk or severity of methemoglobinemia can be increased when Cefonicid is combined with Meloxicam.]
[L01EX15, pexidartinib, The risk or severity of methemoglobinemia can be increased when Pexidartinib is combined with Meloxicam.]
[J01DD12, cefoperazone, The risk or severity of methemoglobinemia can be increased when Cefoperazone is combined with Meloxicam.]
[J01DD01, cefotaxime, The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Meloxicam.]
[J01DC05, cefotetan, The risk or severity of methemoglobinemia can be increased when Cefotetan is combined with Meloxicam.]
[J01DC07, cefotiam, The risk or severity of methemoglobinemia can be increased when Cefotiam is combined with Meloxicam.]
[J01DC01, cefoxitin, The risk or severity of methemoglobinemia can be increased when Cefoxitin is combined with Meloxicam.]
[J01DD03, cefsulodin, The risk or severity of methemoglobinemia can be increased when Cefsulodin is combined with Meloxicam.]
[J01DD02, ceftazidime, The risk or severity of methemoglobinemia can be increased when Ceftazidime is combined with Meloxicam.]
[C03BX03, cicletanine, The therapeutic efficacy of Cicletanine can be decreased when used in combination with Meloxicam.]
[J01DD07, ceftizoxime, The risk or severity of methemoglobinemia can be increased when Ceftizoxime is combined with Meloxicam.]
[J01DD04, ceftriaxone, The risk or severity of methemoglobinemia can be increased when Ceftriaxone is combined with Meloxicam.]
[S01AA27, cefuroxime, The risk or severity of methemoglobinemia can be increased when Cefuroxime is combined with Meloxicam.]
[L01EJ02, fedratinib, The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Meloxicam.]
[L01EX14, entrectinib, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Meloxicam.]
[N07XX11, pitolisant, The risk or severity of adverse effects can be increased when Meloxicam is combined with Pitolisant.]
[J01XX12, lefamulin, The risk or severity of methemoglobinemia can be increased when Lefamulin is combined with Meloxicam.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Meloxicam.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Meloxicam.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Meloxicam is combined with Yohimbine.]
[J01XX09, daptomycin, The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Meloxicam.]
[J01DB01, cephalexin, The risk or severity of methemoglobinemia can be increased when Cephalexin is combined with Meloxicam.]
[J01DB02, cephaloridine, The risk or severity of methemoglobinemia can be increased when Cefaloridine is combined with Meloxicam.]
[J01DB03, cephalothin, The risk or severity of methemoglobinemia can be increased when Cefalotin is combined with Meloxicam.]
[J01DB08, cephapirin, The risk or severity of methemoglobinemia can be increased when Cefapirin is combined with Meloxicam.]
[J01DB09, cephradine, The risk or severity of methemoglobinemia can be increased when Cefradine is combined with Meloxicam.]
[H02AB13, deflazacort, The risk or severity of gastrointestinal irritation can be increased when Deflazacort is combined with Meloxicam.]
[L01FD01, trastuzumab, The risk or severity of methemoglobinemia can be increased when Trastuzumab is combined with Meloxicam.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of methemoglobinemia can be increased when Trastuzumab emtansine is combined with Meloxicam.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of methemoglobinemia can be increased when Trastuzumab deruxtecan is combined with Meloxicam.]
[L01EL03, zanubrutinib, The risk or severity of methemoglobinemia can be increased when Zanubrutinib is combined with Meloxicam.]
[G03AC09, desogestrel, The metabolism of Meloxicam can be decreased when combined with Desogestrel.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Meloxicam.]
[N03AX25, cenobamate, The serum concentration of Meloxicam can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Meloxicam is combined with Givosiran.]
[M09AX08, golodirsen, Meloxicam may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[L01FX13, enfortumab vedotin, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Meloxicam.]
[S01XA12, dexpanthenol, Meloxicam may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Meloxicam can be decreased when combined with Avapritinib.]
[L01XX10, masoprocol, The risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Meloxicam.]
[M01AX21, diacetylrhein, The metabolism of Meloxicam can be decreased when combined with Diacerein.]
[L01FC02, isatuximab, The risk or severity of methemoglobinemia can be increased when Isatuximab is combined with Meloxicam.]
[S01AE06, gatifloxacin, The risk or severity of methemoglobinemia can be increased when Gatifloxacin is combined with Meloxicam.]
[J05AE05, amprenavir, The metabolism of Meloxicam can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Meloxicam is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Meloxicam is combined with Dutasteride.]
[L01EE04, selumetinib, The risk or severity of methemoglobinemia can be increased when Selumetinib is combined with Meloxicam.]
[R02AA03, dichlorobenzyl alcohol, Meloxicam may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The risk or severity of methemoglobinemia can be increased when Dienogest is combined with Meloxicam.]
[L01XD01, porfimer sodium, The risk or severity of methemoglobinemia can be increased when Porfimer sodium is combined with Meloxicam.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Meloxicam.]
[M01AH02, rofecoxib, The risk or severity of adverse effects can be increased when Rofecoxib is combined with Meloxicam.]
[L01XF03, bexarotene, The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Meloxicam.]
[C08CA16, clevidipine, The metabolism of Meloxicam can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Meloxicam can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of methemoglobinemia can be increased when Valpromide is combined with Meloxicam.]
[J01FA13, dirithromycin, The risk or severity of methemoglobinemia can be increased when Dirithromycin is combined with Meloxicam.]
[L01AA02, chlorambucil, The risk or severity of methemoglobinemia can be increased when Chlorambucil is combined with Meloxicam.]
[S03AA08, chloramphenicol, The risk or severity of methemoglobinemia can be increased when Chloramphenicol is combined with Meloxicam.]
[C02AA06, methoserpidine, The therapeutic efficacy of Methoserpidine can be decreased when used in combination with Meloxicam.]
[L01EN02, pemigatinib, The risk or severity of methemoglobinemia can be increased when Pemigatinib is combined with Meloxicam.]
[L01FX17, sacituzumab govitecan, The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Meloxicam.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Meloxicam.]
[L01EX17, capmatinib, The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Meloxicam.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Meloxicam is combined with Dopexamine.]
[D07XB03, fluprednidene, The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Meloxicam.]
[P01BE01, artemisinin, The risk or severity of methemoglobinemia can be increased when Artemisinin is combined with Meloxicam.]
[M01AC04, droxicam, The risk or severity of adverse effects can be increased when Meloxicam is combined with Droxicam.]
[L01EX19, ripretinib, The risk or severity of methemoglobinemia can be increased when Ripretinib is combined with Meloxicam.]
[V08CA05, mangafodipir, Meloxicam may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The risk or severity of methemoglobinemia can be increased when Selpercatinib is combined with Meloxicam.]
[B01AE02, lepirudin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of adverse effects can be increased when Meloxicam is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of methemoglobinemia can be increased when Clomethiazole is combined with Meloxicam.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Dyclonine is combined with Meloxicam.]
[L01XX69, lurbinectedin, The risk or severity of methemoglobinemia can be increased when Lurbinectedin is combined with Meloxicam.]
[C08CA17, levamlodipine, The therapeutic efficacy of Levamlodipine can be decreased when used in combination with Meloxicam.]
[P01BB01, proguanil, The risk or severity of methemoglobinemia can be increased when Proguanil is combined with Meloxicam.]
[L01FX12, tafasitamab, The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Meloxicam.]
[L01XL06, brexucabtagene autoleucel, The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Meloxicam.]
[L01DB04, aclarubicin, The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Meloxicam.]
[L04AC19, satralizumab, The serum concentration of Meloxicam can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The risk or severity of methemoglobinemia can be increased when Chloroquine is combined with Meloxicam.]
[L01EX23, pralsetinib, The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Meloxicam.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meloxicam.]
[G03CA06, chlorotrianisene, The risk or severity of methemoglobinemia can be increased when Chlorotrianisene is combined with Meloxicam.]
[N05AA01, chlorpromazine, The risk or severity of hypertension can be increased when Chlorpromazine is combined with Meloxicam.]
[A10BB02, chlorpropamide, The protein binding of Chlorpropamide can be decreased when combined with Meloxicam.]
[S01AA02, chlortetracycline, The risk or severity of methemoglobinemia can be increased when Chlortetracycline is combined with Meloxicam.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meloxicam.]
[M03BB03, chlorzoxazone, Meloxicam may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of adverse effects can be increased when Meloxicam is combined with Ethenzamide.]
[C10AC01, cholestyramine resin, The serum concentration of Meloxicam can be decreased when it is combined with Cholestyramine.]
[N02BA03, choline salicylate, The therapeutic efficacy of Choline salicylate can be decreased when used in combination with Meloxicam.]
[N06BX18, vinpocetine, The risk or severity of methemoglobinemia can be increased when Vinpocetine is combined with Meloxicam.]
[M01AB08, etodolac, The risk or severity of adverse effects can be increased when Etodolac is combined with Meloxicam.]
[M02AA06, etofenamate, The risk or severity of adverse effects can be increased when Meloxicam is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Meloxicam can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Meloxicam can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of methemoglobinemia can be increased when Fludarabine is combined with Meloxicam.]
[M01AX25, chondroitin sulfates, Meloxicam may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FD06, margetuximab, The risk or severity of methemoglobinemia can be increased when Margetuximab is combined with Meloxicam.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Meloxicam is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Meloxicam can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The risk or severity of methemoglobinemia can be increased when Tepotinib is combined with Meloxicam.]
[L01EX25, umbralisib, The risk or severity of methemoglobinemia can be increased when Umbralisib is combined with Meloxicam.]
[N03AX10, felbamate, The risk or severity of methemoglobinemia can be increased when Felbamate is combined with Meloxicam.]
[M01AE05, fenbufen, The risk or severity of adverse effects can be increased when Meloxicam is combined with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Meloxicam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Meloxicam is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Meloxicam is combined with Finasteride.]
[J01DD08, cefixime, The risk or severity of methemoglobinemia can be increased when Cefixime is combined with Meloxicam.]
[J01DD15, cefdinir, The risk or severity of methemoglobinemia can be increased when Cefdinir is combined with Meloxicam.]
[J01MB07, flumequine, The risk or severity of methemoglobinemia can be increased when Flumequine is combined with Meloxicam.]
[R03BA03, flunisolide, The risk or severity of gastrointestinal irritation can be increased when Flunisolide is combined with Meloxicam.]
[N02BG07, flupirtine, Meloxicam may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Formoterol.]
[S01LA08, bevacizumab, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Meloxicam.]
[L01EK03, tivozanib, The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Meloxicam.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Meloxicam is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Meloxicam can be increased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, The therapeutic efficacy of Dasiglucagon can be decreased when used in combination with Meloxicam.]
[L01XL07, idecabtagene vicleucel, The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Meloxicam.]
[L01FF07, dostarlimab, The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Meloxicam.]
[L01FX22, loncastuximab tesirine, The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Meloxicam.]
[R02AB03, fusafungin, The risk or severity of methemoglobinemia can be increased when Fusafungine is combined with Meloxicam.]
[N02BF01, gabapentin, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Meloxicam.]
[V08CA04, gadoteridol, Meloxicam may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Cinnarizine is combined with Meloxicam.]
[J01MB06, cinoxacin, The risk or severity of methemoglobinemia can be increased when Cinoxacin is combined with Meloxicam.]
[L01XX73, sotorasib, The serum concentration of Meloxicam can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Meloxicam.]
[S03AA07, ciprofloxacin, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Meloxicam.]
[L01XA01, cisplatin, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Meloxicam.]
[N06AB04, citalopram, The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Meloxicam.]
[C03DA05, finerenone, The therapeutic efficacy of Finerenone can be decreased when used in combination with Meloxicam.]
[L01XX74, belzutifan, The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Meloxicam.]
[L01FX23, tisotumab vedotin, The risk or severity of methemoglobinemia can be increased when Tisotumab vedotin is combined with Meloxicam.]
[V09AB03, ioflupane I-123, Meloxicam may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Meloxicam may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09IA09, technetium Tc 99m tilmanocept, Meloxicam may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.]
[V09AX06, florbetaben f-18, Meloxicam may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[A10BB12, glimepiride, The protein binding of Glimepiride can be decreased when combined with Meloxicam.]
[A10BB08, gliquidone, The protein binding of Gliquidone can be decreased when combined with Meloxicam.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Clenbuterol.]
[J01FF01, clindamycin, The risk or severity of methemoglobinemia can be increased when Clindamycin is combined with Meloxicam.]
[N06AX25, St. John's wort extract, The metabolism of Meloxicam can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The risk or severity of methemoglobinemia can be increased when Asciminib is combined with Meloxicam.]
[L02BG06, exemestane, The risk or severity of methemoglobinemia can be increased when Exemestane is combined with Meloxicam.]
[L01XX75, tebentafusp, The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Meloxicam.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Meloxicam.]
[J04BA01, clofazimine, The risk or severity of methemoglobinemia can be increased when Clofazimine is combined with Meloxicam.]
[B01AD11, tenecteplase, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Tenecteplase.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of gastrointestinal bleeding can be increased when Clomipramine is combined with Meloxicam.]
[N03AE01, clonazepam, The risk or severity of methemoglobinemia can be increased when Clonazepam is combined with Meloxicam.]
[S01EA04, clonidine, The therapeutic efficacy of Clonidine can be decreased when used in combination with Meloxicam.]
[C01EB24, mavacamten, The serum concentration of Meloxicam can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Meloxicam may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[C03BA03, clopamide, The therapeutic efficacy of Clopamide can be decreased when used in combination with Meloxicam.]
[L01FX20, tremelimumab, The risk or severity of methemoglobinemia can be increased when Tremelimumab is combined with Meloxicam.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Meloxicam.]
[M02AA08, felbinac, The risk or severity of adverse effects can be increased when Meloxicam is combined with Felbinac.]
[J01CF02, cloxacillin, The risk or severity of methemoglobinemia can be increased when Cloxacillin is combined with Meloxicam.]
[L01XX77, adagrasib, The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Meloxicam.]
[N05AH02, clozapine, The metabolism of Meloxicam can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The risk or severity of methemoglobinemia can be increased when Futibatinib is combined with Meloxicam.]
[L01FE02, panitumumab, The risk or severity of methemoglobinemia can be increased when Panitumumab is combined with Meloxicam.]
[J01GB12, arbekacin, The risk or severity of methemoglobinemia can be increased when Arbekacin is combined with Meloxicam.]
[L01EX11, quizartinib, The risk or severity of methemoglobinemia can be increased when Quizartinib is combined with Meloxicam.]
[H01AC08, somatrogon, The metabolism of Meloxicam can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Cocaine.]
[C02KB01, metyrosine, The therapeutic efficacy of Metyrosine can be decreased when used in combination with Meloxicam.]
[L04AC21, bimekizumab, The metabolism of Meloxicam can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of adverse effects can be increased when Meloxicam is combined with Proquazone.]
[J01CA18, hetacillin, The risk or severity of methemoglobinemia can be increased when Hetacillin is combined with Meloxicam.]
[M04AC01, colchicine, Meloxicam may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XX04, spectinomycin, The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Meloxicam.]
[J01XB01, colistin, The risk or severity of methemoglobinemia can be increased when Colistin is combined with Meloxicam.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of bleeding can be increased when Meloxicam is combined with Omacetaxine mepesuccinate.]
[J01DE02, cefpirome, The risk or severity of methemoglobinemia can be increased when Cefpirome is combined with Meloxicam.]
[L04AA13, leflunomide, The metabolism of Meloxicam can be decreased when combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of hypertension can be increased when Meloxicam is combined with Desflurane.]
[A04AA03, tropisetron, Meloxicam may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The risk or severity of methemoglobinemia can be increased when Ifenprodil is combined with Meloxicam.]
[A10BX03, nateglinide, Meloxicam may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of adverse effects can be increased when Meloxicam is combined with Imidazole salicylate.]
[L01BB07, nelarabine, The risk or severity of methemoglobinemia can be increased when Nelarabine is combined with Meloxicam.]
[J01FA15, telithromycin, The metabolism of Meloxicam can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of gastrointestinal irritation can be increased when Ciclesonide is combined with Meloxicam.]
[B01AC10, indobufen, The risk or severity of adverse effects can be increased when Meloxicam is combined with Indobufen.]
[J05AB14, valganciclovir, Meloxicam may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Meloxicam may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Meloxicam may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Meloxicam may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Meloxicam may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Meloxicam may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of adverse effects can be increased when Valdecoxib is combined with Meloxicam.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Meloxicam is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of hypertension can be increased when Meloxicam is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of adverse effects can be increased when Meloxicam is combined with Parecoxib.]
[J02AC02, itraconazole, The serum concentration of Meloxicam can be decreased when it is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Bemiparin.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Meloxicam.]
[N05BA10, ketazolam, Meloxicam may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of adverse effects can be increased when Meloxicam is combined with Kebuzone.]
[L02BA03, fulvestrant, The risk or severity of methemoglobinemia can be increased when Fulvestrant is combined with Meloxicam.]
[L01EA01, imatinib, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Meloxicam.]
[J02AC04, posaconazole, The metabolism of Meloxicam can be decreased when combined with Posaconazole.]
[S01EE04, travoprost, The therapeutic efficacy of Travoprost can be decreased when used in combination with Meloxicam.]
[S01EE03, bimatoprost, The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meloxicam.]
[C08CA09, lacidipine, The therapeutic efficacy of Lacidipine can be decreased when used in combination with Meloxicam.]
[N03AX09, lamotrigine, The risk or severity of methemoglobinemia can be increased when Lamotrigine is combined with Meloxicam.]
[S01BA03, cortisone, The risk or severity of gastrointestinal irritation can be increased when Cortisone is combined with Meloxicam.]
[N07BC04, lofexidine, The therapeutic efficacy of Lofexidine can be decreased when used in combination with Meloxicam.]
[S01AE04, lomefloxacin, The risk or severity of methemoglobinemia can be increased when Lomefloxacin is combined with Meloxicam.]
[M01AB09, lonazolac, The risk or severity of adverse effects can be increased when Meloxicam is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of adverse effects can be increased when Meloxicam is combined with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of methemoglobinemia can be increased when Loracarbef is combined with Meloxicam.]
[C09AA03, lisinopril, The therapeutic efficacy of Lisinopril can be decreased when used in combination with Meloxicam.]
[A06AD01, magnesium carbonate, Meloxicam may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The therapeutic efficacy of Manidipine can be decreased when used in combination with Meloxicam.]
[D10AF04, meclocycline, The risk or severity of methemoglobinemia can be increased when Meclocycline is combined with Meloxicam.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Meloxicam is combined with Mefenorex.]
[C07AA14, mepindolol, Meloxicam may decrease the antihypertensive activities of Mepindolol.]
[H02AB15, meprednisone, The risk or severity of gastrointestinal irritation can be increased when Meprednisone is combined with Meloxicam.]
[J01DH02, meropenem, The risk or severity of methemoglobinemia can be increased when Meropenem is combined with Meloxicam.]
[J01CA14, methampicillin, The risk or severity of methemoglobinemia can be increased when Metampicillin is combined with Meloxicam.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Meloxicam is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The metabolism of Meloxicam can be decreased when combined with Cyclizine.]
[S01BC10, nepafenac, The risk or severity of adverse effects can be increased when Meloxicam is combined with Nepafenac.]
[C03DA04, eplerenone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Meloxicam.]
[N05AD03, metylperon, Meloxicam may decrease the excretion rate of Melperone which could result in a higher serum level.]
[S01AA22, micronomicin, The risk or severity of methemoglobinemia can be increased when Micronomicin is combined with Meloxicam.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Meloxicam.]
[J01FA03, midecamycin, The risk or severity of methemoglobinemia can be increased when Midecamycin is combined with Meloxicam.]
[J05AF07, tenofovir disoproxil, Meloxicam may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Meloxicam.]
[N06AX07, minaprine, The risk or severity of hypertension can be increased when Minaprine is combined with Meloxicam.]
[J04AB01, cycloserine, The risk or severity of methemoglobinemia can be increased when Cycloserine is combined with Meloxicam.]
[S01XA18, cyclosporine, The risk or severity of renal failure and hypertension can be increased when Meloxicam is combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of hypertension can be increased when Meloxicam is combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Meloxicam can be decreased when combined with Modafinil.]
[C09AA13, moexipril, The therapeutic efficacy of Moexipril can be decreased when used in combination with Meloxicam.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Meloxicam.]
[M02AA02, mofebutazone, The risk or severity of adverse effects can be increased when Meloxicam is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of adverse effects can be increased when Meloxicam is combined with Morniflumate.]
[C03XA02, conivaptan, The therapeutic efficacy of Conivaptan can be decreased when used in combination with Meloxicam.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Meloxicam.]
[L01BC01, cytarabine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Meloxicam.]
[M01AH05, etoricoxib, The risk or severity of adverse effects can be increased when Meloxicam is combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Meloxicam.]
[L01DA01, dactinomycin, The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Meloxicam.]
[G03XA01, danazol, The metabolism of Meloxicam can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Dantrolene.]
[J04BA02, dapsone, The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Meloxicam.]
[L01DB02, daunorubicin, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Meloxicam.]
[C02CC04, debrisoquin, The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Meloxicam.]
[L01DB09, valrubicin, The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Meloxicam.]
[A04AD11, nabilone, The metabolism of Meloxicam can be decreased when combined with Nabilone.]
[M01AX01, nabumetone, The risk or severity of adverse effects can be increased when Nabumetone is combined with Meloxicam.]
[N07BB05, nalmefene, Meloxicam may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Meloxicam.]
[J01AA01, demeclocycline, The risk or severity of methemoglobinemia can be increased when Demeclocycline is combined with Meloxicam.]
[C07AB12, nebivolol, Meloxicam may decrease the antihypertensive activities of Nebivolol.]
[S01GX04, nedocromil, Meloxicam may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Meloxicam can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, The therapeutic efficacy of Nicorandil can be decreased when used in combination with Meloxicam.]
[L02BB02, nilutamide, The risk or severity of methemoglobinemia can be increased when Nilutamide is combined with Meloxicam.]
[L01FE01, cetuximab, The risk or severity of methemoglobinemia can be increased when Cetuximab is combined with Meloxicam.]
[N03AG06, tiagabine, The risk or severity of methemoglobinemia can be increased when Tiagabine is combined with Meloxicam.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Meloxicam is combined with Theodrenaline.]
[M03AC11, cisatracurium, Meloxicam may increase the neuromuscular blocking activities of Cisatracurium.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Meloxicam is combined with Norfenefrine.]
[B01AX05, fondaparinux, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Meloxicam.]
[G04BD08, solifenacin, The risk or severity of hypertension can be increased when Meloxicam is combined with Solifenacin.]
[R02AA02, dequalinium, The risk or severity of methemoglobinemia can be increased when Dequalinium is combined with Meloxicam.]
[A07EC03, olsalazine, The therapeutic efficacy of Olsalazine can be decreased when used in combination with Meloxicam.]
[N06AA01, desipramine, The risk or severity of gastrointestinal bleeding can be increased when Desipramine is combined with Meloxicam.]
[H01BA02, desmopressin, The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Meloxicam is combined with Desmopressin.]
[D07XC02, desoximetasone, The risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Meloxicam.]
[V04CH02, indigo carmine, Meloxicam may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of gastrointestinal irritation can be increased when Desoxycortone is combined with Meloxicam.]
[J01DH03, ertapenem, The risk or severity of methemoglobinemia can be increased when Ertapenem is combined with Meloxicam.]
[C09XA02, aliskiren, The risk or severity of renal failure and hypertension can be increased when Meloxicam is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Meloxicam.]
[M01AE12, oxaprozin, The risk or severity of adverse effects can be increased when Meloxicam is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of methemoglobinemia can be increased when Oxcarbazepine is combined with Meloxicam.]
[S03BA01, dexamethasone, The risk or severity of methemoglobinemia can be increased when Dexamethasone is combined with Meloxicam.]
[L04AB04, adalimumab, The metabolism of Meloxicam can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Meloxicam.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Meloxicam.]
[R05DA09, dextromethorphan, The metabolism of Meloxicam can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of methemoglobinemia can be increased when Paramethadione is combined with Meloxicam.]
[N06AB05, paroxetine, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Meloxicam.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Meloxicam is combined with Clopidogrel.]
[P03AC04, permethrin, Meloxicam may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of methemoglobinemia can be increased when Diazepam is combined with Meloxicam.]
[N03AX07, phenacemide, The risk or severity of methemoglobinemia can be increased when Phenacemide is combined with Meloxicam.]
[V03AH01, diazoxide, The therapeutic efficacy of Diazoxide can be decreased when used in combination with Meloxicam.]
[J01CE05, phenethicillin, The risk or severity of methemoglobinemia can be increased when Pheneticillin is combined with Meloxicam.]
[S01AA29, dibekacin, The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Meloxicam.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of methemoglobinemia can be increased when Phensuximide is combined with Meloxicam.]
[N06AA08, dibenzepin, The risk or severity of gastrointestinal bleeding can be increased when Dibenzepin is combined with Meloxicam.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Meloxicam.]
[R05DA08, pholcodine, Meloxicam may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Diclofenamide can be decreased when used in combination with Meloxicam.]
[S01BC03, diclofenac, The risk or severity of adverse effects can be increased when Diclofenac is combined with Meloxicam.]
[J01CF01, dicloxacillin, The risk or severity of methemoglobinemia can be increased when Dicloxacillin is combined with Meloxicam.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Meloxicam is combined with Foscarnet.]
[A03AA07, dicyclomine, Meloxicam may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Meloxicam may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C02DG01, pinacidil, The therapeutic efficacy of Pinacidil can be decreased when used in combination with Meloxicam.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Pinaverium.]
[L01DC04, ixabepilone, The risk or severity of methemoglobinemia can be increased when Ixabepilone is combined with Meloxicam.]
[L01EB02, erlotinib, The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Meloxicam.]
[L01DB08, pirarubicin, The risk or severity of methemoglobinemia can be increased when Pirarubicin is combined with Meloxicam.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Pirbuterol.]
[C03CA03, piretanide, The therapeutic efficacy of Piretanide can be decreased when used in combination with Meloxicam.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Meloxicam is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Meloxicam can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Meloxicam can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Meloxicam.]
[N02BA11, diflunisal, The therapeutic efficacy of Diflunisal can be decreased when used in combination with Meloxicam.]
[C02DB01, dihydralazine, The therapeutic efficacy of Dihydralazine can be decreased when used in combination with Meloxicam.]
[L02AA02, polyestradiol phosphate, Meloxicam may increase the thrombogenic activities of Polyestradiol phosphate.]
[L01XX24, pegaspargase, The risk or severity of methemoglobinemia can be increased when Pegaspargase is combined with Meloxicam.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Meloxicam is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Meloxicam.]
[N02AA03, hydromorphone, Meloxicam may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of methemoglobinemia can be increased when Lenalidomide is combined with Meloxicam.]
[J05AE08, atazanavir, The metabolism of Meloxicam can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of bleeding can be increased when Treprostinil is combined with Meloxicam.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Meloxicam.]
[V03AB04, pralidoxime, Meloxicam may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Meloxicam can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Meloxicam may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, Meloxicam may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, The risk or severity of methemoglobinemia can be increased when Progabide is combined with Meloxicam.]
[J01CE03, propicillin, The risk or severity of methemoglobinemia can be increased when Propicillin is combined with Meloxicam.]
[N02BB04, propyphenazone, The risk or severity of adverse effects can be increased when Meloxicam is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of adverse effects can be increased when Meloxicam is combined with Proglumetacin.]
[G02AD01, dinoprost, The therapeutic efficacy of Dinoprost can be decreased when used in combination with Meloxicam.]
[C05CA03, diosmin, The metabolism of Meloxicam can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Proparacaine is combined with Meloxicam.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Meloxicam.]
[C09AA06, quinapril, The therapeutic efficacy of Quinapril can be decreased when used in combination with Meloxicam.]
[B01AC07, dipyridamole, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Meloxicam is combined with Dexmethylphenidate.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, The risk or severity of gastrointestinal bleeding can be increased when Quinupramine is combined with Meloxicam.]
[C09AA05, ramipril, The therapeutic efficacy of Ramipril can be decreased when used in combination with Meloxicam.]
[S01XA23, sirolimus, The risk or severity of methemoglobinemia can be increased when Sirolimus is combined with Meloxicam.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Reproterol.]
[S01AX06, resorcinol, Meloxicam may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Meloxicam may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[S02AA12, rifamycin SV, The risk or severity of methemoglobinemia can be increased when Rifamycin is combined with Meloxicam.]
[J04AB05, rifapentine, The risk or severity of methemoglobinemia can be increased when Rifapentine is combined with Meloxicam.]
[D06AX11, rifaximin, The risk or severity of methemoglobinemia can be increased when Rifaximin is combined with Meloxicam.]
[N07XX02, riluzole, The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Meloxicam.]
[N05AX08, risperidone, The risk or severity of hypertension can be increased when Risperidone is combined with Meloxicam.]
[R06AE09, levocetirizine, Meloxicam may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Ropivacaine is combined with Meloxicam.]
[J01MB01, rosoxacin, The risk or severity of methemoglobinemia can be increased when Rosoxacin is combined with Meloxicam.]
[L01EX01, sunitinib, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Meloxicam.]
[A04AD12, aprepitant, The metabolism of Meloxicam can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Meloxicam.]
[L01XG01, bortezomib, The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Meloxicam.]
[G04BE08, tadalafil, The therapeutic efficacy of Tadalafil can be decreased when used in combination with Meloxicam.]
[S01BC05, ketorolac, The risk or severity of adverse effects can be increased when Ketorolac is combined with Meloxicam.]
[C02KX02, ambrisentan, The therapeutic efficacy of Ambrisentan can be decreased when used in combination with Meloxicam.]
[C01EB18, ranolazine, Meloxicam may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of adverse effects can be increased when Meloxicam is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Meloxicam may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Meloxicam is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Meloxicam is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of gastrointestinal bleeding can be increased when Dosulepin is combined with Meloxicam.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Meloxicam.]
[N06AA12, doxepin, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Meloxicam.]
[L01DB01, doxorubicin, The risk or severity of methemoglobinemia can be increased when Doxorubicin is combined with Meloxicam.]
[J01AA02, doxycycline, The risk or severity of methemoglobinemia can be increased when Doxycycline is combined with Meloxicam.]
[N06AB06, sertraline, The risk or severity of bleeding can be increased when Meloxicam is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of hypertension can be increased when Meloxicam is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of hypertension can be increased when Droperidol is combined with Meloxicam.]
[A08AA10, sibutramine, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Meloxicam.]
[C10AA01, simvastatin, The metabolism of Meloxicam can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Meloxicam.]
[A12CA02, sodium sulfate, Meloxicam may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, The therapeutic efficacy of Spirapril can be decreased when used in combination with Meloxicam.]
[R03DA01, dyphylline, Meloxicam may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Sumatriptan is combined with Meloxicam.]
[V04CX07, edrophonium, Meloxicam may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, Meloxicam may decrease the antihypertensive activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of gastrointestinal irritation can be increased when Corticotropin is combined with Meloxicam.]
[J01MA05, temafloxacin, The risk or severity of methemoglobinemia can be increased when Temafloxacin is combined with Meloxicam.]
[J01CA17, temocillin, The risk or severity of methemoglobinemia can be increased when Temocillin is combined with Meloxicam.]
[L01AX03, temozolomide, The risk or severity of methemoglobinemia can be increased when Temozolomide is combined with Meloxicam.]
[M01AC02, tenoxicam, The risk or severity of adverse effects can be increased when Tenoxicam is combined with Meloxicam.]
[G04CA03, terazosin, The therapeutic efficacy of Terazosin can be decreased when used in combination with Meloxicam.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Meloxicam.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Terodiline.]
[C07AA16, tertatolol, Meloxicam may decrease the antihypertensive activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Meloxicam is combined with Tetryzoline.]
[N06AX14, tianeptine, The risk or severity of gastrointestinal bleeding can be increased when Tianeptine is combined with Meloxicam.]
[G03CX01, tibolone, Meloxicam may increase the thrombogenic activities of Tibolone.]
[C09AA02, enalapril, The therapeutic efficacy of Enalapril can be decreased when used in combination with Meloxicam.]
[M01AG02, tolfenamic acid, The risk or severity of adverse effects can be increased when Meloxicam is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of hypertension can be increased when Meloxicam is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Meloxicam.]
[N03AX11, topiramate, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Meloxicam.]
[L02BA02, toremifene, The risk or severity of methemoglobinemia can be increased when Toremifene is combined with Meloxicam.]
[C03CA04, torsemide, The therapeutic efficacy of Torasemide can be decreased when used in combination with Meloxicam.]
[J01AA12, tigecycline, The risk or severity of methemoglobinemia can be increased when Tigecycline is combined with Meloxicam.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Meloxicam is combined with Tramazoline.]
[C09AA10, trandolapril, The therapeutic efficacy of Trandolapril can be decreased when used in combination with Meloxicam.]
[L01AB02, treosulfan, The risk or severity of methemoglobinemia can be increased when Treosulfan is combined with Meloxicam.]
[N05CC01, chloral hydrate, Meloxicam may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Triflusal.]
[H02CA01, trilostane, The risk or severity of methemoglobinemia can be increased when Trilostane is combined with Meloxicam.]
[L02AE04, triptorelin, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Meloxicam.]
[L01AA07, trofosfamide, The risk or severity of methemoglobinemia can be increased when Trofosfamide is combined with Meloxicam.]
[C05CA04, troxerutin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Troxerutin.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Tulobuterol.]
[C02CA06, urapidil, The therapeutic efficacy of Urapidil can be decreased when used in combination with Meloxicam.]
[J01MA04, enoxacin, The risk or severity of methemoglobinemia can be increased when Enoxacin is combined with Meloxicam.]
[L01CA04, vinorelbine, The risk or severity of methemoglobinemia can be increased when Vinorelbine is combined with Meloxicam.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Meloxicam is combined with Ephedrine.]
[N06AX16, venlafaxine, Venlafaxine may increase the antiplatelet activities of Meloxicam.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Meloxicam is combined with Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Meloxicam can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Meloxicam can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of methemoglobinemia can be increased when Epirubicin is combined with Meloxicam.]
[C09AA15, zofenopril, The therapeutic efficacy of Zofenopril can be decreased when used in combination with Meloxicam.]
[N05CF02, zolpidem, The metabolism of Meloxicam can be decreased when combined with Zolpidem.]
[M01AB04, zomepirac, The risk or severity of adverse effects can be increased when Meloxicam is combined with Zomepirac.]
[N03AX15, zonisamide, The therapeutic efficacy of Zonisamide can be decreased when used in combination with Meloxicam.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Meloxicam.]
[B01AD03, anistreplase, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Anistreplase.]
[L01XA02, carboplatin, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Meloxicam.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Meloxicam.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Meloxicam is combined with Iloprost.]
[G02AB03, ergonovine, The risk or severity of hypertension can be increased when Meloxicam is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of hypertension can be increased when Meloxicam is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Meloxicam can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The protein binding of Valproic acid can be decreased when combined with Meloxicam.]
[L03AX05, pidotimod, Meloxicam may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Meloxicam.]
[N05CD04, estazolam, The risk or severity of methemoglobinemia can be increased when Estazolam is combined with Meloxicam.]
[G03CA03, estradiol, Meloxicam may increase the thrombogenic activities of Estradiol.]
[L01XX11, estramustine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Meloxicam.]
[G03CC06, estriol, Meloxicam may increase the thrombogenic activities of Estriol.]
[G03CA57, estrogens, conjugated (USP), Meloxicam may increase the thrombogenic activities of Conjugated estrogens.]
[J04AK02, ethambutol, The risk or severity of methemoglobinemia can be increased when Ethambutol is combined with Meloxicam.]
[R03BA05, fluticasone, The risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Meloxicam.]
[C10AA04, fluvastatin, The metabolism of Meloxicam can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Meloxicam may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Meloxicam is combined with Gepefrine.]
[L02AA03, ethinyl estradiol, Meloxicam may increase the thrombogenic activities of Ethinylestradiol.]
[J04AD03, ethionamide, The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Meloxicam.]
[C01BD05, ibutilide, Meloxicam may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[L01AG01, ethoglucid, The risk or severity of methemoglobinemia can be increased when Etoglucid is combined with Meloxicam.]
[N03AD01, ethosuximide, The risk or severity of methemoglobinemia can be increased when Ethosuximide is combined with Meloxicam.]
[N03AB01, ethotoin, The risk or severity of methemoglobinemia can be increased when Ethotoin is combined with Meloxicam.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Ethyl chloride.]
[S01AA13, fusidic acid, The risk or severity of methemoglobinemia can be increased when Fusidic acid is combined with Meloxicam.]
[J01MB04, pipemidic acid, The risk or severity of methemoglobinemia can be increased when Pipemidic acid is combined with Meloxicam.]
[S02BA08, fluocinolone acetonide, The risk or severity of gastrointestinal irritation can be increased when Fluocinolone acetonide is combined with Meloxicam.]
[M01AG01, mefenamic acid, The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meloxicam.]
[C01DA05, pentaerythritol tetranitrate, Meloxicam may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of gastrointestinal irritation can be increased when Fluticasone furoate is combined with Meloxicam.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Meloxicam is combined with Etilefrine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Etomidate is combined with Meloxicam.]
[L01CB01, etoposide, The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Meloxicam.]
[L04AD02, tacrolimus, The risk or severity of renal failure can be increased when Meloxicam is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of methemoglobinemia can be increased when Fleroxacin is combined with Meloxicam.]
[R06AX12, terfenadine, The metabolism of Meloxicam can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, The risk or severity of methemoglobinemia can be increased when Trimetrexate is combined with Meloxicam.]
[N06AX12, bupropion, Meloxicam may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, The risk or severity of gastrointestinal bleeding can be increased when Fluvoxamine is combined with Meloxicam.]
[R01AX06, mupirocin, The risk or severity of methemoglobinemia can be increased when Mupirocin is combined with Meloxicam.]
[L02AE02, leuprolide, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Meloxicam.]
[M01CB01, gold sodium thiomalate, Meloxicam may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Dextran.]
[V03AF02, dexrazoxane, Meloxicam may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A16AA01, levocarnitine, Meloxicam may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, The therapeutic efficacy of Felodipine can be decreased when used in combination with Meloxicam.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of methemoglobinemia can be increased when Fenfluramine is combined with Meloxicam.]
[M01AE04, fenoprofen, The risk or severity of adverse effects can be increased when Fenoprofen is combined with Meloxicam.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Fentanyl is combined with Meloxicam.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Salbutamol.]
[S01EE01, latanoprost, The therapeutic efficacy of Latanoprost can be decreased when used in combination with Meloxicam.]
[B01AD05, plasmin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Meloxicam.]
[L04AA40, cladribine, The risk or severity of methemoglobinemia can be increased when Cladribine is combined with Meloxicam.]
[N07AX03, cevimeline, Meloxicam may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Meloxicam may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The metabolism of Meloxicam can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of adverse effects can be increased when Meloxicam is combined with Floctafenine.]
[J01CF05, floxacillin, The risk or severity of methemoglobinemia can be increased when Flucloxacillin is combined with Meloxicam.]
[J02AC01, fluconazole, The metabolism of Meloxicam can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Meloxicam may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[H02AA02, fludrocortisone, The risk or severity of gastrointestinal irritation can be increased when Fludrocortisone is combined with Meloxicam.]
[V03AB25, flumazenil, Meloxicam may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of gastrointestinal irritation can be increased when Flumethasone is combined with Meloxicam.]
[N07CA03, flunarizine, The risk or severity of methemoglobinemia can be increased when Flunarizine is combined with Meloxicam.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Meloxicam.]
[D07AC08, fluocinonide, The risk or severity of gastrointestinal irritation can be increased when Fluocinonide is combined with Meloxicam.]
[N06AA14, melitracen, The risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Meloxicam.]
[H02AB03, fluocortolone, The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Meloxicam.]
[V03AZ01, ethanol, The risk or severity of gastrointestinal irritation can be increased when Ethanol is combined with Meloxicam.]
[L01BC09, floxuridine, The risk or severity of methemoglobinemia can be increased when Floxuridine is combined with Meloxicam.]
[S01CB05, fluorometholone, The risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Meloxicam.]
[L01BC02, fluorouracil, The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Meloxicam.]
[N06AB03, fluoxetine, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Meloxicam.]
[N05AF01, flupenthixol, The risk or severity of hypertension can be increased when Meloxicam is combined with Flupentixol.]
[N05CD01, flurazepam, Meloxicam may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meloxicam.]
[N05AG01, fluspirilene, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Fluspirilene.]
[L02BB01, flutamide, The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Meloxicam.]
[V04CX02, folic acid, Meloxicam may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, The risk or severity of methemoglobinemia can be increased when Fosfomycin is combined with Meloxicam.]
[S01AA07, framycetin, The risk or severity of methemoglobinemia can be increased when Framycetin is combined with Meloxicam.]
[L01BC03, tegafur, The risk or severity of methemoglobinemia can be increased when Tegafur is combined with Meloxicam.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Meloxicam is combined with Adrafinil.]
[G01AX06, furazolidone, The risk or severity of hypertension can be increased when Furazolidone is combined with Meloxicam.]
[J05AE10, darunavir, The metabolism of Meloxicam can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Meloxicam.]
[N05CF04, eszopiclone, Meloxicam may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Gallopamil.]
[S01AD09, ganciclovir, Meloxicam may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, The risk or severity of methemoglobinemia can be increased when Barbexaclone is combined with Meloxicam.]
[C10AB04, gemfibrozil, The metabolism of Meloxicam can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of methemoglobinemia can be increased when Telavancin is combined with Meloxicam.]
[L02BX02, degarelix, The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Meloxicam.]
[L01EA02, dasatinib, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Meloxicam.]
[N04BC06, cabergoline, The risk or severity of methemoglobinemia can be increased when Cabergoline is combined with Meloxicam.]
[J05AG04, etravirine, The metabolism of Meloxicam can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of methemoglobinemia can be increased when Methsuximide is combined with Meloxicam.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Alfentanil is combined with Meloxicam.]
[L01EH01, lapatinib, The risk or severity of methemoglobinemia can be increased when Lapatinib is combined with Meloxicam.]
[A10BB01, glyburide, The protein binding of Glyburide can be decreased when combined with Meloxicam.]
[A10BB09, gliclazide, The protein binding of Gliclazide can be decreased when combined with Meloxicam.]
[A10BB07, glipizide, The protein binding of Glipizide can be decreased when combined with Meloxicam.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Meloxicam.]
[C05AE01, nitroglycerin, The therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Meloxicam.]
[C02CA04, doxazosin, The therapeutic efficacy of Doxazosin can be decreased when used in combination with Meloxicam.]
[L01EX02, sorafenib, The risk or severity of methemoglobinemia can be increased when Sorafenib is combined with Meloxicam.]
[C07AB09, esmolol, Meloxicam may decrease the antihypertensive activities of Esmolol.]
[M01CB04, aurothioglucose, Meloxicam may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Meloxicam may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Fluindione.]
[R02AB30, gramicidin, The risk or severity of methemoglobinemia can be increased when Gramicidin D is combined with Meloxicam.]
[C09AA09, fosinopril, The therapeutic efficacy of Fosinopril can be decreased when used in combination with Meloxicam.]
[S01EX01, guanethidine, The therapeutic efficacy of Guanethidine can be decreased when used in combination with Meloxicam.]
[L02AE03, goserelin, The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Meloxicam.]
[P01BX01, halofantrine, The risk or severity of methemoglobinemia can be increased when Halofantrine is combined with Meloxicam.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Meloxicam.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Meloxicam is combined with Halothane.]
[S01FB03, ibopamine, The therapeutic efficacy of Ibopamine can be decreased when used in combination with Meloxicam.]
[N05AH04, quetiapine, The risk or severity of hypertension can be increased when Meloxicam is combined with Quetiapine.]
[N06BX13, idebenone, Meloxicam may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[L01CE02, irinotecan, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Meloxicam.]
[M04AA01, allopurinol, Meloxicam may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Meloxicam.]
[S01XA14, heparin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Heparin.]
[G03DC01, allylestrenol, Meloxicam may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Meloxicam.]
[C01CE02, milrinone, Meloxicam may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of methemoglobinemia can be increased when Altretamine is combined with Meloxicam.]
[N05CA16, hexobarbital, The risk or severity of methemoglobinemia can be increased when Hexobarbital is combined with Meloxicam.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Meloxicam is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Meloxicam can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Meloxicam can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of adverse effects can be increased when Meloxicam is combined with Nimesulide.]
[C09AA04, perindopril, The therapeutic efficacy of Perindopril can be decreased when used in combination with Meloxicam.]
[C02DB02, hydralazine, Meloxicam may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meloxicam.]
[S02BA01, hydrocortisone, The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Meloxicam.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meloxicam.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Meloxicam.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Meloxicam.]
[A12BA02, potassium citrate, The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Meloxicam.]
[V03AB33, hydroxocobalamin, Meloxicam may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of hypertension can be increased when Meloxicam is combined with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Meloxicam.]
[B05AA07, hetastarch, Meloxicam may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of methemoglobinemia can be increased when Hydroxyurea is combined with Meloxicam.]
[J04AB04, rifabutin, The risk or severity of methemoglobinemia can be increased when Rifabutin is combined with Meloxicam.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Meloxicam.]
[M05BA07, risedronic acid, The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of adverse effects can be increased when Meloxicam is combined with Ibuprofen.]
[B05XA08, sodium acetate, Meloxicam may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of methemoglobinemia can be increased when Idarubicin is combined with Meloxicam.]
[L01AA06, ifosfamide, The risk or severity of methemoglobinemia can be increased when Ifosfamide is combined with Meloxicam.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Sufentanil is combined with Meloxicam.]
[N06AA02, imipramine, The risk or severity of gastrointestinal bleeding can be increased when Imipramine is combined with Meloxicam.]
[L01CD01, paclitaxel, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Meloxicam.]
[J01XA02, teicoplanin, The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Meloxicam.]
[R01AD07, tixocortol, The risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Meloxicam.]
[M03BX02, tizanidine, The risk or severity of methemoglobinemia can be increased when Tizanidine is combined with Meloxicam.]
[L01CE01, topotecan, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Meloxicam.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Meloxicam.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Meloxicam.]
[C02CA02, indoramin, The therapeutic efficacy of Indoramin can be decreased when used in combination with Meloxicam.]
[A11HA07, inositol, Meloxicam may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of methemoglobinemia can be increased when Interferon alfa-2a is combined with Meloxicam.]
[L03AB05, interferon alfa-2b, The risk or severity of methemoglobinemia can be increased when Interferon alfa-2b is combined with Meloxicam.]
[N06AX17, milnacipran, The risk or severity of gastrointestinal bleeding can be increased when Milnacipran is combined with Meloxicam.]
[S01XA28, varenicline, Meloxicam may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Articaine.]
[A10BH01, sitagliptin, Meloxicam may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Meloxicam may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Meloxicam may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[C10AA06, cerivastatin, The metabolism of Meloxicam can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Meloxicam is combined with Anagrelide.]
[C07AA01, alprenolol, Meloxicam may decrease the antihypertensive activities of Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Quinethazone can be decreased when used in combination with Meloxicam.]
[V03AB01, ipecac, Meloxicam may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of gastrointestinal bleeding can be increased when Iprindole is combined with Meloxicam.]
[N06AF05, iproniazid, The metabolism of Meloxicam can be decreased when combined with Iproniazid.]
[N06AF01, isocarboxazid, The risk or severity of hypertension can be increased when Meloxicam is combined with Isocarboxazid.]
[S01EC03, dorzolamide, The therapeutic efficacy of Dorzolamide can be decreased when used in combination with Meloxicam.]
[P01AX06, atovaquone, The risk or severity of methemoglobinemia can be increased when Atovaquone is combined with Meloxicam.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Meloxicam.]
[C09AA16, imidapril, The therapeutic efficacy of Imidapril can be decreased when used in combination with Meloxicam.]
[N01AB06, isoflurane, The risk or severity of hypertension can be increased when Isoflurane is combined with Meloxicam.]
[J04AC01, isoniazid, The risk or severity of methemoglobinemia can be increased when Isoniazid is combined with Meloxicam.]
[J05AX05, inosine pranobex, Meloxicam may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Meloxicam is combined with Isoprenaline.]
[D10BA01, isotretinoin, Meloxicam may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Meloxicam is combined with Isoxsuprine.]
[B01AE06, bivalirudin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Bivalirudin.]
[J01FA07, josamycin, The risk or severity of methemoglobinemia can be increased when Josamycin is combined with Meloxicam.]
[S01AA24, kanamycin, The risk or severity of methemoglobinemia can be increased when Kanamycin is combined with Meloxicam.]
[L04AC07, tocilizumab, The metabolism of Meloxicam can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Meloxicam may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Meloxicam is combined with Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Meloxicam can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The metabolism of Meloxicam can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of adverse effects can be increased when Meloxicam is combined with Ketoprofen.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Meloxicam is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Meloxicam can be increased when combined with Abatacept.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Meloxicam is combined with Arbutamine.]
[N04BC09, rotigotine, The risk or severity of hypertension can be increased when Meloxicam is combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of methemoglobinemia can be increased when Nalidixic acid is combined with Meloxicam.]
[C07AG01, labetalol, Meloxicam may decrease the antihypertensive activities of Labetalol.]
[N04BB01, amantadine, Meloxicam may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C02AA05, deserpidine, The therapeutic efficacy of Deserpidine can be decreased when used in combination with Meloxicam.]
[A06AX03, lubiprostone, Meloxicam may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Meloxicam.]
[J01CA11, amdinocillin, The risk or severity of methemoglobinemia can be increased when Amdinocillin is combined with Meloxicam.]
[J01CA08, amdinocillin pivoxil, The risk or severity of methemoglobinemia can be increased when Pivmecillinam is combined with Meloxicam.]
[L01DC03, mitomycin, The risk or severity of methemoglobinemia can be increased when Mitomycin is combined with Meloxicam.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Meloxicam.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Lidoflazine.]
[J01FF02, lincomycin, The risk or severity of methemoglobinemia can be increased when Lincomycin is combined with Meloxicam.]
[S01AA21, amikacin, The risk or severity of methemoglobinemia can be increased when Amikacin is combined with Meloxicam.]
[N06BA13, armodafinil, The metabolism of Meloxicam can be decreased when combined with Armodafinil.]
[C03DB01, amiloride, The therapeutic efficacy of Amiloride can be decreased when used in combination with Meloxicam.]
[N02CA07, lisuride, The risk or severity of hypertension can be increased when Lisuride is combined with Meloxicam.]
[N06AA07, lofepramine, The risk or severity of gastrointestinal bleeding can be increased when Lofepramine is combined with Meloxicam.]
[L01AD02, lomustine, The risk or severity of methemoglobinemia can be increased when Lomustine is combined with Meloxicam.]
[A07DA03, loperamide, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of methemoglobinemia can be increased when Lorazepam is combined with Meloxicam.]
[C10AA02, lovastatin, The metabolism of Meloxicam can be decreased when combined with Lovastatin.]
[J01AA04, lymecycline, The risk or severity of methemoglobinemia can be increased when Lymecycline is combined with Meloxicam.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Meloxicam.]
[L01EG01, temsirolimus, The risk or severity of methemoglobinemia can be increased when Temsirolimus is combined with Meloxicam.]
[B05XA11, magnesium chloride, Meloxicam may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Meloxicam may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The risk or severity of methemoglobinemia can be increased when Magnesium sulfate is combined with Meloxicam.]
[L01BA05, pralatrexate, Meloxicam may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Meloxicam can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Meloxicam.]
[N06AA21, maprotiline, Meloxicam may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Meloxicam.]
[L01AA05, mechlorethamine, The risk or severity of methemoglobinemia can be increased when Mechlorethamine is combined with Meloxicam.]
[M02AA18, meclofenamic acid, The risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of methemoglobinemia can be increased when Medazepam is combined with Meloxicam.]
[C01AA08, medigoxin, Meloxicam may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[P01BC02, mefloquine, The risk or severity of methemoglobinemia can be increased when Mefloquine is combined with Meloxicam.]
[J01FG01, pristinamycin, The risk or severity of methemoglobinemia can be increased when Pristinamycin is combined with Meloxicam.]
[C03BA05, mefruside, The therapeutic efficacy of Mefruside can be decreased when used in combination with Meloxicam.]
[B01AB06, nadroparin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Dalteparin.]
[L01AA03, melphalan, The risk or severity of methemoglobinemia can be increased when Melphalan is combined with Meloxicam.]
[N06DX01, memantine, Meloxicam may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Meloxicam may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Meloxicam is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of methemoglobinemia can be increased when Mephenytoin is combined with Meloxicam.]
[N03AA01, mephobarbital, The risk or severity of methemoglobinemia can be increased when Methylphenobarbital is combined with Meloxicam.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Meloxicam is combined with Mepivacaine.]
[G04BX16, tiopronin, Meloxicam may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[L02BG01, aminoglutethimide, The risk or severity of methemoglobinemia can be increased when Aminoglutethimide is combined with Meloxicam.]
[C03BC01, mersalyl, The therapeutic efficacy of Mersalyl can be decreased when used in combination with Meloxicam.]
[N05AX13, paliperidone, The risk or severity of hypertension can be increased when Meloxicam is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Meloxicam.]
[A10BA02, metformin, Meloxicam may decrease the excretion rate of Metformin which could result in a higher serum level.]
[H01CB03, lanreotide, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Meloxicam.]
[J01AA05, methacycline, The risk or severity of methemoglobinemia can be increased when Metacycline is combined with Meloxicam.]
[N07BC02, methadone, Meloxicam may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, The risk or severity of hypertension can be increased when Meloxicam is combined with Metamfetamine.]
[J05AF05, lamivudine, Meloxicam may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of methemoglobinemia can be increased when Metharbital is combined with Meloxicam.]
[S01EC05, methazolamide, The therapeutic efficacy of Methazolamide can be decreased when used in combination with Meloxicam.]
[L01XD04, aminolevulinic acid, The risk or severity of methemoglobinemia can be increased when Aminolevulinic acid is combined with Meloxicam.]
[J01XX05, methenamine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Meloxicam.]
[G02CB05, metergoline, The risk or severity of hypertension can be increased when Meloxicam is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Meloxicam can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Meloxicam may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, The risk or severity of methemoglobinemia can be increased when Methohexital is combined with Meloxicam.]
[A11HA02, pyridoxine, Meloxicam may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The risk or severity of hypertension can be increased when Meloxicam is combined with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Meloxicam.]
[D05BA02, methoxsalen, Meloxicam may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of hypertension can be increased when Meloxicam is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meloxicam.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Meloxicam.]
[V04CG05, methylene blue, The metabolism of Meloxicam can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Meloxicam.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Meloxicam.]
[H02AB04, methylprednisolone, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Meloxicam.]
[D07AC14, methylprednisolone aceponate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Meloxicam.]
[N03AF03, rufinamide, The risk or severity of methemoglobinemia can be increased when Rufinamide is combined with Meloxicam.]
[G03EK01, methyltestosterone, The risk or severity of methemoglobinemia can be increased when Methyltestosterone is combined with Meloxicam.]
[N02CA04, methysergide, The risk or severity of hypertension can be increased when Methysergide is combined with Meloxicam.]
[A03FA01, metoclopramide, The risk or severity of methemoglobinemia can be increased when Metoclopramide is combined with Meloxicam.]
[C03BA08, metolazone, The therapeutic efficacy of Metolazone can be decreased when used in combination with Meloxicam.]
[C07AB02, metoprolol, Meloxicam may decrease the antihypertensive activities of Metoprolol.]
[P01AB01, metronidazole, The risk or severity of methemoglobinemia can be increased when Metronidazole is combined with Meloxicam.]
[V04CD01, metyrapone, Meloxicam may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[J01CA10, mezlocillin, The risk or severity of methemoglobinemia can be increased when Mezlocillin is combined with Meloxicam.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Meloxicam is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Meloxicam can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of adverse effects can be increased when Meloxicam is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Parnaparin.]
[N05CD08, midazolam, Meloxicam may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Meloxicam.]
[G03XB01, mifepristone, The metabolism of Meloxicam can be decreased when combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Tinzaparin.]
[J05AH01, zanamivir, Meloxicam may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Meloxicam.]
[J01AA08, minocycline, The risk or severity of methemoglobinemia can be increased when Minocycline is combined with Meloxicam.]
[D11AX01, minoxidil, The therapeutic efficacy of Minoxidil can be decreased when used in combination with Meloxicam.]
[J01FA11, miocamycin, The risk or severity of methemoglobinemia can be increased when Miocamycin is combined with Meloxicam.]
[L01DC02, plicamycin, The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Meloxicam.]
[L01AX01, mitobronitol, The risk or severity of methemoglobinemia can be increased when Mitobronitol is combined with Meloxicam.]
[L01XX23, mitotane, The risk or severity of methemoglobinemia can be increased when Mitotane is combined with Meloxicam.]
[L01DB07, mitoxantrone, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Meloxicam.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Meloxicam is combined with Lisdexamfetamine.]
[L03AA03, molgramostim, The risk or severity of methemoglobinemia can be increased when Molgramostim is combined with Meloxicam.]
[L03AC01, aldesleukin, The risk or severity of methemoglobinemia can be increased when Aldesleukin is combined with Meloxicam.]
[C01BD01, amiodarone, The metabolism of Meloxicam can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of gastrointestinal bleeding can be increased when Amitriptyline is combined with Meloxicam.]
[A04AA05, palonosetron, Meloxicam may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of methemoglobinemia can be increased when Latamoxef is combined with Meloxicam.]
[L04AB05, certolizumab pegol, The metabolism of Meloxicam can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Ammonium chloride.]
[L04AA52, ofatumumab, The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Meloxicam.]
[L01EX03, pazopanib, The risk or severity of methemoglobinemia can be increased when Pazopanib is combined with Meloxicam.]
[L04AA06, mycophenolic acid, The risk or severity of methemoglobinemia can be increased when Mycophenolic acid is combined with Meloxicam.]
[N05CA02, amobarbital, The risk or severity of methemoglobinemia can be increased when Amobarbital is combined with Meloxicam.]
[P01BA06, amodiaquine, The risk or severity of methemoglobinemia can be increased when Amodiaquine is combined with Meloxicam.]
[N06AA17, amoxapine, The risk or severity of gastrointestinal bleeding can be increased when Amoxapine is combined with Meloxicam.]
[N03AB05, fosphenytoin, The risk or severity of methemoglobinemia can be increased when Fosphenytoin is combined with Meloxicam.]
[C07AA12, nadolol, Meloxicam may decrease the antihypertensive activities of Nadolol.]
[J01CA04, amoxicillin, The risk or severity of methemoglobinemia can be increased when Amoxicillin is combined with Meloxicam.]
[J01CF06, nafcillin, The risk or severity of methemoglobinemia can be increased when Nafcillin is combined with Meloxicam.]
[V03AB15, naloxone, The metabolism of Meloxicam can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Meloxicam can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Meloxicam is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Meloxicam.]
[M02AA12, naproxen, The risk or severity of adverse effects can be increased when Naproxen is combined with Meloxicam.]
[A10BG01, troglitazone, The metabolism of Meloxicam can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Meloxicam.]
[S01AA10, natamycin, The risk or severity of methemoglobinemia can be increased when Natamycin is combined with Meloxicam.]
[N04BX01, tolcapone, Meloxicam may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[L01CD02, docetaxel, The risk or severity of methemoglobinemia can be increased when Docetaxel is combined with Meloxicam.]
[L02BG04, letrozole, The risk or severity of methemoglobinemia can be increased when Letrozole is combined with Meloxicam.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Meloxicam is combined with Neomycin.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Meloxicam is combined with Remifentanil.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Meloxicam is combined with Tirofiban.]
[N05AX14, iloperidone, The risk or severity of hypertension can be increased when Meloxicam is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Meloxicam.]
[S01AA19, ampicillin, The risk or severity of methemoglobinemia can be increased when Ampicillin is combined with Meloxicam.]
[L03AX16, plerixafor, Meloxicam may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, The risk or severity of methemoglobinemia can be increased when Netilmicin is combined with Meloxicam.]
[N06AX23, desvenlafaxine, The risk or severity of gastrointestinal bleeding can be increased when Desvenlafaxine is combined with Meloxicam.]
[C09CA07, telmisartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Meloxicam.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Valaciclovir is combined with Meloxicam.]
[C01CE01, inamrinone, Meloxicam may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of methemoglobinemia can be increased when Amsacrine is combined with Meloxicam.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Meloxicam is combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Meloxicam can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Nicergoline is combined with Meloxicam.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Meloxicam.]
[C08CA05, nifedipine, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of adverse effects can be increased when Meloxicam is combined with Niflumic acid.]
[C08CA06, nimodipine, The therapeutic efficacy of Nimodipine can be decreased when used in combination with Meloxicam.]
[C08CA07, nisoldipine, The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Meloxicam.]
[N05CD02, nitrazepam, The risk or severity of methemoglobinemia can be increased when Nitrazepam is combined with Meloxicam.]
[C08CA08, nitrendipine, The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Meloxicam.]
[R07AX01, nitric oxide, Meloxicam may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, The risk or severity of methemoglobinemia can be increased when Nitrofurantoin is combined with Meloxicam.]
[N05CF03, zaleplon, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Meloxicam.]
[N04BC05, pramipexole, Meloxicam may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, The therapeutic efficacy of Nitroprusside can be decreased when used in combination with Meloxicam.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Meloxicam is combined with Nitrous oxide.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Meloxicam.]
[S01AE02, norfloxacin, The risk or severity of methemoglobinemia can be increased when Norfloxacin is combined with Meloxicam.]
[C02KX01, bosentan, The therapeutic efficacy of Bosentan can be decreased when used in combination with Meloxicam.]
[N06AA10, nortriptyline, The risk or severity of gastrointestinal bleeding can be increased when Nortriptyline is combined with Meloxicam.]
[R05DA07, noscapine, The metabolism of Meloxicam can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Meloxicam is combined with Eptifibatide.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Meloxicam is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Reviparin.]
[H01CB02, octreotide, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Meloxicam.]
[S02AA16, ofloxacin, The risk or severity of methemoglobinemia can be increased when Ofloxacin is combined with Meloxicam.]
[J01FA05, oleandomycin, The risk or severity of methemoglobinemia can be increased when Oleandomycin is combined with Meloxicam.]
[L04AC04, rilonacept, The metabolism of Meloxicam can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Meloxicam can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of gastrointestinal bleeding can be increased when Opipramol is combined with Meloxicam.]
[N02AA02, opium, Meloxicam may decrease the excretion rate of Opium which could result in a higher serum level.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Meloxicam is combined with Orciprenaline.]
[B01AD07, reteplase, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Ancrod.]
[G04CA02, tamsulosin, Meloxicam may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[M05BA08, zoledronic acid, The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Zoledronic acid.]
[J01CF04, oxacillin, The risk or severity of methemoglobinemia can be increased when Oxacillin is combined with Meloxicam.]
[A14AA08, oxandrolone, The metabolism of Meloxicam can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, Meloxicam may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of methemoglobinemia can be increased when Oxolinic acid is combined with Meloxicam.]
[C07AA02, oxprenolol, Meloxicam may decrease the antihypertensive activities of Oxprenolol.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Meloxicam is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Meloxicam is combined with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The risk or severity of adverse effects can be increased when Meloxicam is combined with Oxyphenbutazone.]
[S01AA04, oxytetracycline, The risk or severity of methemoglobinemia can be increased when Oxytetracycline is combined with Meloxicam.]
[J04AA01, aminosalicylic acid, The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Meloxicam.]
[N05AH05, asenapine, The risk or severity of hypertension can be increased when Meloxicam is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Danaparoid.]
[J04AB30, capreomycin, The risk or severity of methemoglobinemia can be increased when Capreomycin is combined with Meloxicam.]
[N05CC05, paraldehyde, The risk or severity of methemoglobinemia can be increased when Paraldehyde is combined with Meloxicam.]
[H02AB05, paramethasone, The risk or severity of gastrointestinal irritation can be increased when Paramethasone is combined with Meloxicam.]
[C02KC01, pargyline, The therapeutic efficacy of Pargyline can be decreased when used in combination with Meloxicam.]
[A07AA06, paromomycin, The risk or severity of methemoglobinemia can be increased when Paromomycin is combined with Meloxicam.]
[J01MA03, pefloxacin, The risk or severity of methemoglobinemia can be increased when Pefloxacin is combined with Meloxicam.]
[G04BD11, fesoterodine, Meloxicam may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Meloxicam may decrease the antihypertensive activities of Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Penfluridol.]
[J01CE09, penicillin G procaine, The risk or severity of methemoglobinemia can be increased when Procaine benzylpenicillin is combined with Meloxicam.]
[S01AA14, penicillin G, The risk or severity of methemoglobinemia can be increased when Benzylpenicillin is combined with Meloxicam.]
[J01CE02, penicillin V, The risk or severity of methemoglobinemia can be increased when Phenoxymethylpenicillin is combined with Meloxicam.]
[N05CA01, pentobarbital, The risk or severity of methemoglobinemia can be increased when Pentobarbital is combined with Meloxicam.]
[L01XX08, pentostatin, The risk or severity of methemoglobinemia can be increased when Pentostatin is combined with Meloxicam.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Meloxicam is combined with Pentoxifylline.]
[N04BC02, pergolide, The risk or severity of hypertension can be increased when Meloxicam is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Perhexiline.]
[L01FX01, edrecolomab, The risk or severity of methemoglobinemia can be increased when Edrecolomab is combined with Meloxicam.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Meloxicam.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Meloxicam is combined with Phenazopyridine.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Phenelzine is combined with Meloxicam.]
[B01AA02, phenindione, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Phenindione.]
[N03AA02, phenobarbital, The risk or severity of methemoglobinemia can be increased when Phenobarbital is combined with Meloxicam.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Meloxicam.]
[B01AA04, phenprocoumon, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Meloxicam.]
[V03AB36, phentolamine, The therapeutic efficacy of Phentolamine can be decreased when used in combination with Meloxicam.]
[M02AA01, phenylbutazone, The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meloxicam.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Meloxicam.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Meloxicam.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Meloxicam.]
[L01XF02, alitretinoin, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Meloxicam.]
[L04AB06, golimumab, The metabolism of Meloxicam can be increased when combined with Golimumab.]
[S01AE08, besifloxacin, The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Meloxicam.]
[S01AE05, levofloxacin, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Meloxicam.]
[L02BB03, bicalutamide, The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Meloxicam.]
[B02BA01, vitamin K1, Meloxicam may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Cidofovir is combined with Meloxicam.]
[C08CX01, mibefradil, The therapeutic efficacy of Mibefradil can be decreased when used in combination with Meloxicam.]
[C07AA03, pindolol, Meloxicam may decrease the antihypertensive activities of Pindolol.]
[J01CA12, piperacillin, The risk or severity of methemoglobinemia can be increased when Piperacillin is combined with Meloxicam.]
[J05AE01, saquinavir, The metabolism of Meloxicam can be decreased when combined with Saquinavir.]
[L01AX02, pipobroman, The risk or severity of methemoglobinemia can be increased when Pipobroman is combined with Meloxicam.]
[N06BX03, piracetam, Meloxicam may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Meloxicam.]
[S01BC06, piroxicam, The risk or severity of adverse effects can be increased when Piroxicam is combined with Meloxicam.]
[J01DD16, cefditoren, The risk or severity of methemoglobinemia can be increased when Cefditoren is combined with Meloxicam.]
[J01MA11, grepafloxacin, The risk or severity of methemoglobinemia can be increased when Grepafloxacin is combined with Meloxicam.]
[J01CA02, pivampicillin, The risk or severity of methemoglobinemia can be increased when Pivampicillin is combined with Meloxicam.]
[N02CX01, pizotyline, The risk or severity of hypertension can be increased when Meloxicam is combined with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Meloxicam can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Meloxicam.]
[B01AC13, abciximab, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Alteplase.]
[A10BG02, rosiglitazone, Meloxicam may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[L02BG03, anastrozole, The risk or severity of methemoglobinemia can be increased when Anastrozole is combined with Meloxicam.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Meloxicam.]
[L04AC08, canakinumab, The metabolism of Meloxicam can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Meloxicam is combined with Polymyxin B.]
[C03AA05, polythiazide, The therapeutic efficacy of Polythiazide can be decreased when used in combination with Meloxicam.]
[J05AE03, ritonavir, The serum concentration of Meloxicam can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, Meloxicam may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Meloxicam.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Meloxicam.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Meloxicam.]
[C07AB01, practolol, Meloxicam may decrease the antihypertensive activities of Practolol.]
[C02CA01, prazosin, The therapeutic efficacy of Prazosin can be decreased when used in combination with Meloxicam.]
[L01AA08, prednimustine, The risk or severity of methemoglobinemia can be increased when Prednimustine is combined with Meloxicam.]
[S03BA02, prednisolone, The risk or severity of methemoglobinemia can be increased when Prednisolone is combined with Meloxicam.]
[H02AB07, prednisone, The risk or severity of methemoglobinemia can be increased when Prednisone is combined with Meloxicam.]
[M02AA16, feprazone, The risk or severity of adverse effects can be increased when Meloxicam is combined with Feprazone.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Prilocaine is combined with Meloxicam.]
[P01BA03, primaquine, The risk or severity of methemoglobinemia can be increased when Primaquine is combined with Meloxicam.]
[N03AA03, primidone, The risk or severity of methemoglobinemia can be increased when Primidone is combined with Meloxicam.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Meloxicam which could result in a higher serum level.]
[C01BA02, procainamide, Meloxicam may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Procaine is combined with Meloxicam.]
[L01XB01, procarbazine, The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Meloxicam.]
[C10AB05, fenofibrate, The metabolism of Meloxicam can be decreased when combined with Fenofibrate.]
[G03DA04, progesterone, The metabolism of Meloxicam can be decreased when combined with Progesterone.]
[N05AA03, promazine, The risk or severity of hypertension can be increased when Promazine is combined with Meloxicam.]
[R06AD02, promethazine, The metabolism of Meloxicam can be decreased when combined with Promethazine.]
[C01BC03, propafenone, Meloxicam may decrease the antihypertensive activities of Propafenone.]
[A03AB05, propantheline, Meloxicam may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[N05AC01, periciazine, The risk or severity of hypertension can be increased when Meloxicam is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of hypertension can be increased when Propiomazine is combined with Meloxicam.]
[L01XH02, romidepsin, The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Meloxicam.]
[N01AX10, propofol, The risk or severity of hypertension can be increased when Meloxicam is combined with Propofol.]
[C07AA05, propranolol, Meloxicam may decrease the antihypertensive activities of Propranolol.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Meloxicam is combined with Rizatriptan.]
[B01AC09, epoprostenol, The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Meloxicam can be decreased when combined with Montelukast.]
[J04AD01, prothionamide, The risk or severity of methemoglobinemia can be increased when Protionamide is combined with Meloxicam.]
[N06AA11, protriptyline, The risk or severity of gastrointestinal bleeding can be increased when Protriptyline is combined with Meloxicam.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Meloxicam is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of hypertension can be increased when Meloxicam is combined with Aripiprazole.]
[N07XX07, dalfampridine, Meloxicam may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Meloxicam may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, The risk or severity of methemoglobinemia can be increased when Pyrazinamide is combined with Meloxicam.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Meloxicam.]
[P01BD01, pyrimethamine, The risk or severity of methemoglobinemia can be increased when Pyrimethamine is combined with Meloxicam.]
[P01AX05, quinacrine, The risk or severity of methemoglobinemia can be increased when Quinacrine is combined with Meloxicam.]
[C01BA01, quinidine, The risk or severity of methemoglobinemia can be increased when Quinidine is combined with Meloxicam.]
[P01BC01, quinine, The risk or severity of methemoglobinemia can be increased when Quinine is combined with Meloxicam.]
[A02BA02, ranitidine, Meloxicam may decrease the excretion rate of Ranitidine which could result in a higher serum level.]
[C02AA01, rescinnamine, The therapeutic efficacy of Rescinnamine can be decreased when used in combination with Meloxicam.]
[C02AA02, reserpine, The therapeutic efficacy of Reserpine can be decreased when used in combination with Meloxicam.]
[J05AP01, ribavirin, Meloxicam may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The risk or severity of methemoglobinemia can be increased when Rifampicin is combined with Meloxicam.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Meloxicam is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Meloxicam is combined with Ritodrine.]
[J01AA09, rolitetracycline, The risk or severity of methemoglobinemia can be increased when Rolitetracycline is combined with Meloxicam.]
[J01FA06, roxithromycin, The risk or severity of methemoglobinemia can be increased when Roxithromycin is combined with Meloxicam.]
[N02BA05, salicylamide, The risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of methemoglobinemia can be increased when Sulfasalazine is combined with Meloxicam.]
[S01BC08, salicylic acid, The risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylic acid.]
[N05CA06, secobarbital, The risk or severity of methemoglobinemia can be increased when Secobarbital is combined with Meloxicam.]
[N04BD01, selegiline, The risk or severity of hypertension can be increased when Meloxicam is combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of methemoglobinemia can be increased when Obinutuzumab is combined with Meloxicam.]
[D06BA01, silver sulfadiazine, The risk or severity of methemoglobinemia can be increased when Silver sulfadiazine is combined with Meloxicam.]
[J01GB08, sisomicin, The risk or severity of methemoglobinemia can be increased when Sisomicin is combined with Meloxicam.]
[A12CD01, sodium fluoride, Meloxicam may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Meloxicam may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, Meloxicam may decrease the antihypertensive activities of Sotalol.]
[L01CD04, cabazitaxel, The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Meloxicam.]
[J01FA02, spiramycin, The risk or severity of methemoglobinemia can be increased when Spiramycin is combined with Meloxicam.]
[C03DA01, spironolactone, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Meloxicam.]
[M05BA01, etidronic acid, The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Etidronic acid.]
[M05BA04, alendronic acid, The risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Meloxicam.]
[L01CD03, paclitaxel poliglumex, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Meloxicam.]
[C01DA14, isosorbide mononitrate, Meloxicam may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[H02CA04, levoketoconazole, The metabolism of Meloxicam can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Meloxicam may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of adverse effects can be increased when Meloxicam is combined with Tiaprofenic acid.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meloxicam.]
